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a b s t r a c t
Since the pioneering work dealing with the synthesis and physicochemical aspects of den-
drimers, a predictable and tunable set of compositions for therapeutic, scaffolding and
imaging systemshasbeen reported. These arewell documented, butmanyhot issues should
be examined and reviewed. Herein, a review is given on dendritic nanopolymers and their
applications that show promise in the field of regenerative medicine. This review begins
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with a brief overview on research merging nanotechnology and regenerative medicine.
Fundamentals of the synthesis and macromolecular structure of dendritic polymers are
provided. Dendrimers fulfill the requirements as carriers for gene, nucleic acids, bioac-
tive molecules and peptide/protein delivery aimed at modulate the cells functions, in vitro
and in vivo. However, to make use of this potential, toxicological, drug-loading capacity,
surface engineering and host–guest chemistries in dendrimers must be addressed and
thus are also discussed. We focus on recent work involving dendrimers with applications
in tissue engineering and the central nervous system. Due to their innovative character,
applications beyond drug delivery systems became possible, namely as scaffolding and
chemoattractants for tissue regeneration, and implantable biodegradable nanomaterial-
based medical devices integrated with drug delivery functions (theranostics). Finally, we
highlight promising areas for further research and comment on how and why dendrimer
and dendron technology should be viewed as the next generation of biomaterials for the
21st century.
© 2010 Elsevier Ltd. All rights reserved.
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1. Introduction
The 20th century has witnessed impressive innova-
tions in polymer synthesis and advances in the design of
biodegradable chemistries. These achievements permit the
synthesis of macromolecules with multiple compositions
and novel architectures possessing unique physicochem-
ical and biological properties. Synthetic polymers can
be divided into four key architectural classes: linear,
cross-linked, branched, and dendritic structures. The
first three types have been studied extensively in the
past. The fourth comprises the more recently developed,
nature-inspired dendrimers, and derivatives thereof are
reviewed here. These are highly branched and nanospher-
ical macromolecules, and are a prominent example of
nano-polymer revolution. The first reports on dendrimers
synthesis are attributed to Vögtle group [1] in the late
1970s, followed by the work of Tomalia et al. [2] in
the early 1980s. These novel structures differ from those
of typical linear polymers, since their architecture is
extremely precise and controlled, conferring them with
tunable and predictable molecular weights, biodegrad-
ability and biocompatibility. This chemistry revolution
ignited many possibilities, and it is not surprising that
we now witness their exploitation in a variety of medical
applications.
In this review, we report on the noteworthy scien-
tific advances and most recent literature, dealing with
the dendritic polymers nanotechnology, and briefly dis-
cuss the convergence of nanotechnology and regenerative
medicine. Discussion of the fundamental dendrimers will
include the numerous synthetic strategies reported for
the preparation of dendrimer-based materials. Recent
advances in dendrimer surface engineering are described,
leading to novel and promising complexities (architec-
tures and chemical functionalities), such as dendronized
polymers. Interesting features reported for dendronized
polymers are also discussed, as well as suggestions for
potential applications, such as tissue engineering (TE), cen-
tral nervous system (CNS), gene delivery and theranostics.
In 1959, Feynman [3] coined nanotechnology as a
futuristic approach to the development of materials atom
by atom. The ultimate goal of nanotechnology can be
described as the ability to apply the nanoscale principles
and work at the atomic, molecular and supramolecular
levels (on the range of 1–100nm) to understand, and
create material systems by assembling molecules into
objects. Nanotechnology provides solutions for the trans-
formation of biosystems and provides a broad collection
of technologies, techniques and processes for real life
purposes. Current and potential applications of nanotech-
nology in medicine include research involving diagnostic
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Fig. 1. A typical dendron structure resembles the architecture of a tree,
and provides figurative meaning to Tomalia inspiration from nature
and a poetic analogy of the dendrimers to nature’s architecture and
geometric forms (photo obtained from Casa Milà also known as La
Pedrera-Barcelona).
devices, drug delivery vehicles, nanoscale surgery, biosen-
sors and body part repair/regeneration and cancer therapy.
In turn, regenerative medicine uncovers fundamental bio-
logical processes, self-repairing, self-replicating, and tissue
regeneration mechanisms and offers inspiration models to
nanotechnology [4–6]. Several examples of applications of
nanotechnology in regenerative medicine will be provided
further, but the currently undergoing explosive develop-
ments are summarized in Table 1, including examples from
references [7–77]. As may be seen by the examples in
Table 1, exploratory research in nanotechnology is consid-
ered to be emerging, disruptive andmultidisciplinary [78].
Since it offers ever more exciting promises of new diag-
noses and treatment routes, it can greatly impact every
aspect of society. Consequently, there have been tremen-
dous investments in this area [6].
2. Dendritic polymers–dendrimers and dendrons:
fundamentals and biotechnological applications
Dendrimers are a unique class of synthetic polymers
which play an important role in emerging nanotechnology
[79,80]. The term “dendrimer” (from Greek: dendra, tree
andmeros, part of) describes the architecture of this emerg-
ing class of polymeric macromolecules which possess 3-D
features that resemble a tree (Fig. 1).
Presently, the dendritic architectural class can be
divided into four subclasses: random hyperbranched poly-
mers, dendrigraft polymers, dendrons, and dendrimers
[80]. More than 100 different dendrimers and 1000 surface
chemistries are currently known.
A typical dendrimer structure consists of three basic
components (Fig. 2): a multi-functional central core (©)
where other molecules can be trapped [81], branched
units (Y) that emanates from the central core and exter-
nal capping-groups (E). The highly regular branching units
are organized in layers called “generations”, and represent
the repeating monomer unit of these synthetic macro-
molecules [80]. Therefore, dendrimers can be synthesized
fromsimplebranchedmonomerunits, in aprecise and con-
Fig. 2. Schematic representation of the dendrimer typical structure.
trolled fashion from trunk to branch and to leaf “surface
groups”.
Dendrimers may be designed to provide a quite ver-
satile choice of external functional groups [74] in order
to reduce cytotoxicity, enhance transepithelial transport
[81,82], promote interactionwith couplingmolecules such
as natural-based polymers [83] and create fluorescent-
probes [84]. The surface groups may also act as passive or
reactive gates controlling entry or departure of molecules
from the dendrimer interior. Surface properties may also
allow control clearance and biodistribution in the body.
Their size, shape, and topology, as well as flexibility and
surface functionality, may be controlled at the molecular
level (all three architectural components), which makes
them not only useful building blocks and carrier molecules
at the nanometer level, but also able to precisely manip-
ulate both molecular weight and chemical composition.
This new class of synthetic [85–87], highly branched,
nanospherical macromolecules presents unique features
in comparison to the traditional linear, cross-linked and
branched polymers [80,88], thus many researchers have
explored their potential in many biological applications.
An advantage is related with the fact that the narrow
molecularweight distributions (Mw/Mn =1.0000–1.05) can
provide reproducible pharmacokinetic behavior [80].
There are various classes of dendrimers, but the ones
that have attracted a great deal of attention are: (i) glyco-
dendrimers and (ii) peptide dendrimers. Glycodendrimers
have exhibited great potential as drug carriers. The term
‘glycodendrimer’ has been used to describe dendrimers
that include carbohydrates in their architecture. The vast
majority of glycodendrimers have saccharide residues on
their outer surface, but glycodendrimers containing a
sugar unit as the central core, from which all branches
emanate, have also been described. Generally, glycoden-
drimers can be classified as: (i) carbohydrate-centered,
(ii) carbohydrate-based and (iii) carbohydrate-coated den-
drimers. The laterwill be further discussed in Section 3, the
so-called dendronized polymers.
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Table 1
Nanotechnology applications in regenerative medicine.
Application(s) Examples of material structures, devices and systems at nanoscale Reference(s)
Targeted and controlled
drug delivery
Nanoshells (layered colloids with a non-conducting nanoparticle core covered by a thin metal shell)
and nanorods (e.g., copolymers, gold) are used in combination with specific wavelengths of lights and
heat technology for cancer therapy
[7–10]
Dendrimer-antibody or peptide-major histocompatibility complex ligand constructs for sensitive
detection and drug delivery (e.g., doxorubicin) to T cells. Using this type of strategy guided therapy is
possible
[11,12]
Quantum dots (central core of elements of groups II- or III–VI of the periodic table, i.e. CdSe, CdTe,
PbSe, ZnSe, GaAs, InP, GaN capped with ZnS) cross-linked to antibody conjugates (e.g., monoclonal
antibodies, biotin, avidin), oligonucleotides molecule ligands to render them specific to biological
targets
[13–15]
Liposomes (lipid-based vesicles with size ranging from 50 to 100nm) and surface modified-liposomes
(e.g., PEGylated lipids trademarked as QuSomesTM) for drug delivery and treatment of several diseases
(e.g., cancer therapy and inflammatory arthritis). Surface modified sialyl Lewis X-liposomes
demonstrate their efficiency as a targeted drug delivery system for preventing stenosis after
angioplasty
[16–20]
Fullerenes (i.e. clusters of 60 carbon atoms) for intracellular drug delivery, as their structure mimic
that of clathrin known to mediate endocytosis
[21–23]
Medical devices Contrast agents as the superparamagnetic nanoparticles (e.g., FePt, iron oxide, PLGA coated iron oxide
with size ranging from 10 to 20nm) and quantum-dot-based nanoparticles (e.g., biotinylated
gadolinium-annexin A5-streptavidin) for use in magnetic resonance imaging (MRI). Radiopaque
iodinated polymeric nanoparticles for X-ray imaging applications have also been developed
[24–28]
T1 agents to target folate receptors using dendrimer-based agent that can be decorated with both
ligands and gadolinium
[29]
Proteins such as antibodies, antigens, and enzymes can be immobilized on protein chips for
application in early diagnosis of disease, tailored drug therapy, and detection of various pathogens
[30–34]
Silicon nanopore membranes for find applications in haemodialysis and haemofiltration [35]
Cell/tissue engineering Carbon single-wall nanotube (size <100nm) sheets to develop artificial muscle [36,37]
Systems to determine or reduce immune rejection of organs. [38,39]
Nanostructured materials for nerve, bone, and cartilage regeneration [40–42]
Collagen-dendrimer hydrogels for ocular tissue engineering [43]
Gene delivery Polycationic polymers (e.g., SuperFect® dendrimers, poly-(l-lysine)) as synthetic non-viral vectors
with decrease cytotoxicity
[44–46]
Cationic liposomes and formulations (e.g., lipid-coated magnetic nanoparticles, liposomal bubbles) for
the delivery of oligonucleotides to different cells. Liposomal formulations for triggered release of
siRNA have also been developed
[47–52]
Molecular-tags
(in vitro and in vivo
imaging)
Semi-conductor nanocrystals quantum dots (e.g., CdSe, ZnS), nanocrystals that fluoresce in different
colours depending on their sizes and may find application for targeting multiple types of cells in living
organisms. The quantum dots may be also linked with ligand molecules for receptor labeling and
visualization
[53–56]
Metal–chelate–dendrimer coupled to monoclonal antibody for radiotherapy and imaging [12]
Fluorescent labelled-nanoparticles (e.g., fluorescein isothiocyanate (FITC)-labeled PAMAM
dendrimer-drug conjugate) for assessing cellular uptake
[57]
Gold and silver nanoparticles (size <50nm) for molecular detection and separation [58–60]
Gold nanorods for cancer-cell imaging [10]
Biosensors, bioanalysis and
microfluidics
Carbon-nanotubes arrays as immunosensors for detection of antigen-antibody binding [61]
Electrochemical immunosensor based on dendrimer-assisted self-assembled monolayers
functionalized with enzyme-tagged antibody
[62,63]
Dendrimer-modified electrodes for application as biosensors. PAMAM–CdS nanocomposites for
biological assays
[64–67]
Nanowire field-effect transistors for detection of biomolecules [68,69]
High-throughput (e.g., extracellular matrix microarray, high-throughput screening of gene functions)
analysis as a tool for evaluating cell fate and drug discovery
[70–72]
Theranostics
(i.e. combined
therapeutics and
diagnostic)
Polymer-based nanosystems for therapeutic and diagnostic of several diseases [73,74]
Liposomes (e.g., polyethylene glycol (PEG)-coated liposomes-doxorubicin,
111Indium-vinorelbine-liposomes) for imaging, therapy and diagnosis of variety of cancers
[75,76]
Fullerenes (e.g., PEG-coated fullerenes containing gadolinium ions) for MRI and efficient
photodynamic therapy of tumors
[77]
Sadler and Tam [89] broadly defined peptide den-
drimers as “radial orwedge-like branchedmacromolecules
consisting of a peptidyl branching core and/or covalently
attached surface functional units”. Thus, this definition
includes any dendrimer with an amino acid core, branch-
ing units, surface functional groups or any combination of
the three as a peptide dendrimer. In dendrimer synthe-
sis, aminoacids are also appealing building blocks because
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peptide-coupling techniques can be used. Despite this,
most research on dendritic polymers has been conducted
with glycodendrimers.
The synthesis and applications of glycodendrimers
and peptide dendrimers have been reviewed [89–92].
Two different synthetic strategies are currently explored
for synthesizing structurally well-defined dendritic poly-
mers, namely the divergent [88,93] and convergent
growth [94–96] approaches. Most commercially avail-
able dendrimers, such as the Tomalia’s poly(amidoamine)
(PAMAM) dendrimers from Dendritech Inc. (Midland, MI,
USA) and poly(propyleneimine) (PPI) dendrimers from
DSM (Geleen, Netherlands) are produced by the divergent
method. This method involves in situ branch-component
construction in step-wise and iterative stages around a
desired core to produce core–shell structures. In the con-
vergentmethod (Fréchet approach) [97], dendrons are syn-
thesized and then are anchored to a multi-functional core.
This strategy can provide the best structural control, e.g.,
purification of low molecular dendrons at interim stages
of the growth, while dendrons can be decorated step-by-
step at the periphery and core [98,99] (e.g., by phosphines
at the end of the branches, then by amines at the core).
This method affords the so-called “Christmas tree”-like
compounds. Moreover, Fréchet-type dendrimers can be
designed to obtain various (un)symmetrical dendrimers
[100], such as amphiphilic dendrimers. Both strategies
offer advantages and disadvantages, and the appropriate
route depends mainly on the type of monomer used, or
“buildingblocks”, and thedesired structure. Although there
are different routes to synthesize dendrimers, their maxi-
mum size is typically in the order of ∼10–20nm [79,101].
Recently, a novel synthetic route has been proposed for
new low-cost Priostar dendrimers [102,103].
The unique characteristics of dendritic polymers make
possible their use in a wide range of applications. Among
the myriad of possibilities, dendritic polymers can find
applications as a delivery carrier of drugs [81,104,105],
and on the development of synthetic vaccines [106,107],
anti-tumor systems [108,109] and immunology [110,111].
Other applications in the bioscience field include blood
anticoagulant [112] and microbicidal [113–116] activ-
ities. For example, Jiang at al. [117] reported on a
poly-(l-lysine) (PLL) dendrimer with a polyanionic outer
surface consisting of 32 naphthalene disulfonate units,
also known as Vivagel (Starpharma Ltd., Melbourne, Aus-
tralia), found to be safe and prevent HIV-1 infection by
binding to receptors on the viral coat. The promising
results support the investigation of VivaGel in phase II
clinical trials in humans [118]. In another study, Saha
and Roy [119] synthesized HIV-1 protease inhibitors
analogs consisting of a N-substituted oligoglycine pep-
toids bearing N-acetylglucosamine residues. The resultant
glycosilated peptoids were synthesized by an iterative
strategy involving mono N-alkylation and bromoacetyla-
tion. Dendrimer-based DDS have also proved to effectively
enhance anti-viral activity in vitro, by reducing the viral
load [120,121]. Dendrimers have also been useful in prion
research [122–124] since cationic dendrimers are shown to
perturb peptide fibrillation in a process dependent on the
nature of the charged groups on the dendrimer surface.
Dendrimersmimicking the surface structure of proteins
involved in angiogenesis inhibition have been developed
for use in anti-tumor systems [125,126]. Angiogenesis,
an important process for tumor growth, is initiated by
angiogenic factors, such as vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (b-FGF).
These growth factors bind to their receptors on endothelial
cells with the dependence of heparin or heparan sul-
fate proteoglycan (HSPG) in extracellular matrix (ECM).
The participation of binding to heparin or HSPG leads to
potential targets for anti-angiogenic activity. Endostatin,
a well-known endogenous angiogenic protein binds to
heparin or HSPG and inhibits some functions of endothe-
lial cells, resulting in potent suppression of angiogenesis.
To find new potent angiogenic inhibitors, Shimamura
at al. [126] focused their attention on the characteristic
positive-charge-rich surface of endostatin and the inter-
action between its arginine residues and either heparin
or HSPG. This group designed novel arginine-rich den-
drimers, TX-1943 (8 Arg residues) and TX-1944 (16 Arg
residues), whichmimic the surface structure of endostatin,
and evaluated their anti-angiogenic ability, in vitro and in
vivo. In vitro studies demonstrated that both dendrimers
bound to heparin [126]. During this study, it was also
observed that angiogenesis inhibition of b-FGF stimulated
proliferation and tube formation of endothelial cells. How-
ever, in vitro the anti-angiogenic activity of TX-1944 was
stronger than that of TX-1943. Moreover, both types of
dendrimers exhibitedpotent anti-angiogenic activity in the
chicken embryo chorioallantoic membrane assay, in vivo.
These data suggest that arginine dendrimer can be used
to suppress or prevent the growth and metastasis of solid
tumors.
Innovative syntheticprocedureshave increasedaccessi-
bility to the functionalizationof dendrimerswith transition
metals in the core, finding interesting applications in catal-
ysis [127–130]. Several authors have proposed the use of
dendrimers todevelop complexeswithmetals, includingPt
[131], Ag [132,133], Fe [134], Cu and Ni [135]. Most metal-
lodendrimers are built fromorganic skeletons, in particular
from PAMAM or PPI type dendrimers. Despite the impres-
sive properties of metallodendrimers, special attention to
this topic is not presented here, as several good reviews
summarize aspects dealing with the synthesis and prop-
erties [136–138], as well as characterization techniques
[139,140]. A number of examples are also known for fluo-
rinated [141] and phosphorus-containing dendrimers and
dendrons [142–144].
Applications of dendrimers in more traditional tech-
nologies such as coatings and inks have also been explored,
as the spherical shape of dendrimers can promote special
rheological characteristics [145]. The versatility of den-
drimer also explains their importance in optic, electronics
and magnetic applications [146–148]. A recent work [149]
proposed the use of PAMAM dendrimers adsorbed onto
native oxide surfaces of silicon wafers as a strategy to
direct the integration of metal electrodeposition with sil-
icon microfabrication processes, and selective deposition
by dendrimer patterning.
Alonso et al. [150] described the development of an
amperometric enzyme electrode for glucose monitoring.
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This high sensitive electrode consisted of the electro-
static immobilization of the enzyme glucose oxidase onto
C and Pt electrodes modified with mixed ferrocene-
cobaltocenium dendrimers. This work showed that higher
generation dendrimers can be more efficient electron
transfer mediators, and can find applications as sensors.
In another study [151], PPI dendrimer cores functional-
ized with octamethylferrocenyl units were deposited onto
a Pt electrode. Amperometric biosensors for glucose were
prepared by immobilization of glucose oxidase (GOX) on
the electrodes and their applications as hydrogen peroxide
and glucose sensor were investigated. It was also shown
that electrodes modified with polymethylferrocenyl den-
drimer promote the redox reactions of hydrogen peroxide
with an efficiency affected by structural characteristics of
the dendrimers when low working potentials are used.
The biosensors developed possess a good linear response
region, and superior sensitivity and reproducibility as com-
pared with other ferrocene-mediated glucose sensors.
Yao et al. [65] reported an enzymefield-effect transistor
(ENFET) for determining glucose. This biosensor was pro-
duced with dendrimer encapsulated Pt nanoparticles and
GOX via a layer-by-layer self-assembly method. This work
demonstrated that thedevelopedbiosensorpossessesgood
stability, enhanced sensitivity and extended lifetime as
compared to conventional ones. Buschbeck and Lang [152]
have proposed the surface-modification of low generation
dendrimers with triethylene glycol methyl ether units to
develop ionophores for chemical sensors.
Another work [153] using erythrocyte ghosts demon-
strated that the addition of fourth-generation PAMAM
dendrimer and PAMAM-OH has a dual effect on the activ-
ity of human erythrocyte membrane acetylcholinesterase
(AChE). Low dendrimer (25!M) concentrations caused a
statistically significant increase of the enzyme activity.
Inhibition of AChE was observed for dendrimer concentra-
tions higher than 100!M. The efficiency of the inhibition
was similar for both amine- and hydroxyl-terminated
PAMAM dendrimers; however, the maximum activation
occurred for a different range of dendrimer concentra-
tion; 25!M for PAMAM-OH (G4) and 100!M for PAMAM
(G4). The initical explanation attributed the changes of
AChE activity upon addition of dendrimers to alteration
in protein structure, but the effect may be associated
with the structural changes in the whole membrane. A
study reported by Shcharbin et al. [154] aimed to clar-
ify whether AChE inhibition was a result of direct action
of dendrimers on the enzyme or indirect changes in lipid
bilayer of membrane. By performing fluorescence analysis
it was demonstrated that anionic and cationic dendrimers
changed AChE conformation and the strongest effect was
induced by carboxylic-terminated PAMAM dendrimers
(G3.5). It was also demonstrated that change in the AChE
conformation and catalytic activity depended on type and
concentration of the dendrimer.
Kubát et al. [155], investigated the interaction of por-
phyrins in aqueous solution with PAMAM dendrimers of
different generations and external groups. In that work,
the binding of porphyrins to PAMAM dendrimers was
controlled mainly by electrostatic interactions between
porphyrins and terminal groups of PAMAM dendrimers
(amine or carboxylic groups), and depended on both por-
phyrin peripheral functionalization and pH of the solution.
Both low and high-generation dendrimers formed com-
plexes with porphyrins.
Shcharbin et al. [156,157] have studied the interac-
tion of serum albumins with cationic dendrimers. In their
first study [156], they investigated the interaction of a
fourth-generation PAMAM dendrimer and serum albu-
mins from human (HAS) and bovine (BSA) origin. This
study demonstrated that serum albumins and PAMAM G4
dendrimer form complexes with stoichiometry of 4–6:1
for PAMAM:HSA and 4–5:1 for PAMAM:BSA molar ratio.
Results obtained from circular dichroism, fluorescence
polarization and zeta-potential experiments have shown
that dendrimers did not significantly change the secondary
structure of proteins, and interactions betweenprotein and
dendrimer were weak. Based on the 3-D crystal structures
of HSA and BSA, they identified five non-specific anionic
regions for binding of cationic dendrimers. Another study
[157] investigated the effect of the generation of PAMAM
dendrimers (G2 and G6) on the binding to bovine serum
albumin (fatty acids free and loaded with different fatty
acids). This comprehensive work showed that although
proteins loaded with fatty acids have more stable struc-
tures and were less sensitive to the action of dendrimers,
BSA-fatty acid complexes bound to PAMAM dendrimers.
These results suggested that the efficiency of the inter-
action depends on the fatty acids loaded on the protein,
e.g., PAMAM dendrimers were able to compete with BSA
for fatty acids if two or three fatty acids were loaded per
protein.
An important characteristic of dendritic molecules is
their improved solubility in a large number of organic
solvents [158,159]. An understanding of the interfacial
interactions is important to the biomedical applications
of these polymers. In this respect, it has been shown that
dendrimers areable to change their conformationondiffer-
ent alkanethiol surfaces due to their flexibility. Abdelhady
et al. [160] conducted an atomic force microscopy (AFM)
study to understand the factors affecting the interactions
of fourth-generation PAMAM dendrimers with substrates
of defined surface chemistry. Their results also suggest that
the surface conformation of such dendrimermolecules can
depend upon the nature of the functionalized substrates.
Recently, Allabashi at al. [161] reported an easymethod
for manufacturing composite filters cross-linked with
silylated dendritic polymers and cyclodextrins (CD). Tri-
ethoxysilylated derivatives of PPI dendrimer, PPI and
polyglycerol hyperbranched polymers and ˇ-cyclodextrin
(ˇ-CD) were impregnated into Al2O3, SiC and TiO2 mem-
branes and tested for the removal of a variety of organic
pollutants from water. The data proved their efficiency on
removing up to 99% polycyclic aromatic hydrocarbons, 93%
of themonocyclic aromatic hydrocarbons, and up to 43% of
pesticides, among others.
Cromer et al. [162] have proposed the use of func-
tionalized dendrimers as endotoxin sponges. Using in
vitro and in vivo models of septic shock, they demon-
strated that PAMAM dendrimers partially modified by
hydrophobic groups effectively bind and sequester bacte-
rial lipopolysaccharides. Therefore, these systems may be
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useful for the therapy of gram-negative sepsis. The stud-
ies of Labieniec et al. [163] provided the first evidence of
the therapeutic effect of fourth-generation PAMAM den-
drimers. These were found to lower plasma glucose and
suppress long-termmarkers of diabetic hyperglycaemia, in
vivo.
Despite themanyadvantages and superior performance
of the dendrimers highlighted herein, with the exception
of PAMAM, PPI, polyphosphane, and triallyl phenol, few
can be obtained with high generations. Synthesis of high-
generation dendrimers, useful for exploring the nature
of the dendritic architecture, depends critically on the
nature of the constituent monomers, their reactivities, and
on the method of their preparation. Krishna et al. [164]
showed that poly(propyl ether imine) (PETIM) dendrimers
(G3) possessing alcohol, amine, nitrile, ester or carboxylic
acid groups at the peripheries can be obtained. More-
over, during their studies it was demonstrated that PETIM
dendrimers with carboxylic acid groups were non-toxic
over two different cell lines: human breast cancer T47D
and African green monkey kidney (CV-1) cells. Jayamuru-
gan and Jayaraman [165] also reported the synthesis of
high-generation PETIM dendrimers, obtaining PETIM den-
drimers up to G6 by carrying out simple iterative steps
consisting of two alternate Michael additions and two
reduction reactions. Thedisadvantage is that theprocedure
is long, but the overall yields are quite good for lower gen-
erations. They have shown that it is possible to tailor the
peripheries of these dendrimers by introducing different
groups such as alcohols, amines, carboxylic acids, esters, or
nitriles, and up to 128 external groups, thereby opening up
new properties and possibilities for several applications.
The well-defined hyperbranched structure of den-
drimers has motivated chemists to explore the possibility
for mimicking protein functions with dendritic macro-
molecules [166], such as O2-carrying haemoproteins [167]
and coenzyme B12 [168]. In the next section, this issue will
be explored further.
3. Dendritic polymers in regenerative medicine
3.1. Drug delivery applications of dendrimers and
dendronized polymers
The development of nanotechnology-based efficient
drug delivery systems for small molecules, proteins and
DNA has attracted a great deal of attention over the last
few years. Unlike traditional polymers, dendrimers can
be obtained in precise molecular weights even at high
generations, which as previously highlighted can pro-
vide a reproducible pharmacokinetic behavior. This feature
makes themideal candidates fordrugdeliveryapplications.
However, an efficient drug delivery systems should meet
other criteria, such as: (i) structural control over the size
and shape of drug or imaging-agent cargo-space; (ii) bio-
compatibility, non-toxic polymer/pendant functionality;
(iii) precise, nanoscale-container and/or scaffolding prop-
erties with high drug-loading capacity; (iv) well-defined
scaffolding and/or surfacemodifiable functionality for cell-
specific targetingmoieties; (v) lack of immunogenicity; (vi)
appropriate cellular adhesion and internalization, (vii) ade-
quate bio-elimination or biodegradation; (viii) controlled
or stimuli-responsive drug release features; (ix) molecular
level isolation and protection of the drug against inactiva-
tion during transit to target cells; (x) minimal non-specific
cellular and blood–protein binding properties; (xi) ease of
consistent, reproducible, clinical grade synthesis.
In regenerative medicine, the control of cells’ behavior
at the nanoscale is addressed via cell-adhesion receptors.
The surface of eukaryotic cells is covered with an array
of glycoconjugates (e.g., glycoprotein’s and glycolipids).
Extracellularly, carbohydrates in some of the glycocon-
jugates play a key role in the process of cell–cell and
cell–pathogen adhesion. Furthermore, they also partici-
pate in such fundamental processes as glycan cross-linking
in the ECM. Intracellularly, carbohydrate receptors are
involved in such key biological processes as protein fold-
ing and sorting of proteins (e.g., the degradative lysosomal
enzymes). It is the weak binding of most carbohydrate
ligands for their protein receptors, that require these carbo-
hydrates to be clustered to attain biologically meaningful
affinities towards their receptors (e.g., lectin type) [169].
In order to refine the biological activities and drug deliv-
ery by dendritic polymers, efficient carbohydrate ligands
of the glycodendrimer-type are emerging as potent ligands
for carbohydrate-binding proteins. Such type of molecules
can be obtained through surface engineering using a carbo-
hydrate coating on the dendrimeric system, the so-called
dendronized polymers (Fig. 3). Dendrimers modified with
terminal carbohydrate polymers constitute a new class
of biopolymers with many interesting applications. Such
type of dendrimers have been proposed by the Roy and
co-workers [170], and can be synthesized for example,
by functionalization of the dendrimers with lactogroups,
the so-called lactodendrimers. Thus, dendronized poly-
mers can be conveniently synthesized with good yield
using both divergent and convergent approaches, or by
chemoenzymatic approaches [171]. Another advantage of
these systems is related with the chemical nature of the
synthetic linker and the possibility of tailoring the type
of glycosidic linkages in these compounds, which gives us
additional flexibility to meet demands from the point of
view of hydrophobicity, and biodegradability [169]. More-
over, these compounds can grow to considerable size by
successive cycles of branching, which give them a unique
possibility to vary the degree of carbohydrate clustering
required by the carbohydrate receptors. Potentially, such
molecules can be used for the treatment and control of
metabolic disorders involving carbohydrates, and protec-
tion against certain types of infections.
Dendronized polymers with a variety of shapes, core
molecules, carbohydrate residues and valences have been
made available for the biological evaluation. This new class
of materials is expected to exhibit entirely new properties
since the structuresmight have sizes larger than 10nmand
different surface properties [86]. In fact, the linking of ter-
minal sugar residues, such as heparin, on dendrimers can
create amultivalentdisplay thatmimic cell-surface glycans
[172]. This strategy showed that heparin dendrimers pro-
mote FGF-2-mediatedmitogen-activated kinase activation
inL6myoblasts. Thus, theseglycodendrimers canmodulate
heparin-protein interactions.
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Fig. 3. Comparison of the structure of (A) PAMAM dendrimer (G2), and (B) PAMAM dendrimer bearing carbohydrate end groups (dendronized polymer).
It has been found [173] that high-generation den-
drimers (G7) with amine capping-groups causes haemol-
ysis and changes the morphology of red cells, since
they bind to membranes of cells (negatively charged)
in a non-specific manner and can cause toxicity in vitro
and in vivo. Similar findings were reported by Doman-
ski et al. [174], who investigated the effect of PAMAM
dendrimers’ concentration and generation (G2, G3 and
G4) on human red blood cells. This paper demonstrated
that erythrocyte shape changed and was accompanied
by dendrimer-induced haemolysis when these cells were
exposed to nanoparticles concentrations ranging between
1nM and 1!M. Moreover, it was conclusive that when
higher dendrimer generation was used, a lower con-
centration of PAMAM dendrimer was needed to cause
haemolysis. These observations were supported by the
work of Jevprasesphant et al. [175]. The cytotoxicity of
unmodified PAMAM dendrimers towards Caco-2 cells was
appreciably higher for cationic (whole generation) com-
pared with anionic (half generation) dendrimers and for
both types increased with increasing size (generation) and
concentration. King Heiden et al. [176] also demonstrated
that PAMAM dendrimers amine-terminated (G4) are toxic
and attenuated growth and development of zebrafish
embryos at sub-lethal concentrations. However, PAMAM
dendrimers carboxylic-terminated (G3.5) were not toxic
to zebrafish embryos. Dutta et al. [177] study corrobo-
rated previous findings that demonstrated the cytotoxic
behavior of PPI dendrimer amine-terminated (G5), in vitro.
Recently, Libieniec et al. [163] showed cytotoxic effects
of PAMAM dendrimers (G4), in vivo. It was found that
PAMAMdendrimers increasedmortality of streptozotocin-
diabetic rats. Neerman et al. [178] reported melamine
dendrimers were developed, and their potential as a vehi-
cle for drug delivery applications was investigated. The
preliminary in vitro study showed a decrease in Clone
9 cells viability at 0.1mgmL−1 as compared to that of
cells cultured in the presence of dextran. For the in vivo
study, mice were administered with increasing concen-
trations of dendrimer via intraperitoneal (i.p.) injection.
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At a higher concentration (160mgkg−1), 100% mortality
was observed and histopathological data revealed hep-
atoxicity. At low concentrations (2.5–40mgkg−1) of the
dendrimers, no mortality was seen, and no hepatic dam-
age was found. These data suggest that the toxicity of the
melamine-based dendrimer is comparable to the cationic
PAMAMdendrimers, and further studies need to be carried
out to evaluate their potential as DDS.
Surface engineered dendrimers with carbohydrates
should make it also possible to avoid the cytotoxic effects
of cationic and high-generation dendrimers and reduce
the haemolytic toxicity by reduction/shielding of the pos-
itive charge on the dendrimer surface, while enhancing
the peripheral congestion to improve container proper-
ties. The development of strategies for the synthesis of
dendrimers based on novel cores and branches [179] con-
tinues to be one of the important aspects of dendrimer
chemistry due to the need for tailoring rigidity and den-
sity to refine drug release kinetics. Sashiwa and co-workers
[83,180–182] have established the synthesis of a variety of
chitosan-dendrimer dendronized polymers mainly by two
procedures: (i) dendrimers bearing aldehyde and a spacer
are synthesized, and then these are reacted with chitosan
by reductive N-alkylation, and (ii) linking of chitosan to the
dendrimer surface. The first approach has the advantage
of no cross-linking during the reaction. The second allows
the use of commercially available amino-dendrimers, such
as PAMAM and poly(ethyleneimine) (PEI) dendrimers. At
least two binding points are available; however, this can
be a drawback as it can cause an undesired cross-linking.
Following these studies, Oliveira et al. [183] proposed to
surface engineer PAMAM dendrimers with water-soluble
carboxymethylchitosan (CMCht), to develop novel sphere-
like nanoparticles for possible application as carriers to
deliver intracellularlybioactivemolecules. These are aimed
at control of the behavior of stem cells, namely their
proliferation and differentiation. Dubber and Lindhorst
[184] reported the synthesis of a carbohydrate-centered
PAMAMdendrimers. First, D-glucosewas converted into its
per-aminoethyl-functionalized derivative, whichwas then
submitted to the multi-step reaction to obtain the PAMAM
branches. Domanski et al. [185] also showed that thio-
phosphate dendrimers (G5) were neither haemotoxic nor
cytotoxicwithin the concentration range 100pM to 10!M,
thus being good candidates for drug delivery. A marked
decrease in the cytotoxicity of amine-terminated PAMAM
dendrimerswasnotedwhen the surfacewasmodifiedwith
the addition of six lauroyl or four PEG chains [175]. Dutta et
al. [177] demonstrated that the surface modification of PPI
(G5) dendrimerswithmannose andN-tert-butoxycarbonyl
(t-Boc) decreases haemolitic toxicity and cytotoxicity over
HepG2 and COS-7 cell lines, in vitro. Moreover, an in
vivo study [186] in Wistar rats showed that administra-
tion of PPI dendrimers (G5) caused haemolysis and tissue
degeneration, after 24h. On the contrary, no signs of tox-
icity were observed in animals to which surface-modified
PPI dendrimers were administered, suggesting that func-
tionalization of dendrimers leads to drastic reduction of
toxicity and increases biocompatibility. Makimura et al.
[187] investigated glycodendrimers with a lysine core and
with different carbohydrates on the exterior. Compared to
Fig. 4. Dendronized polymer loaded with a drug: incorporation in the
bulk (A) and covalent bonding to functional groups (B).
the mono-functional structure, l-lysine dendrimers with
8 or 16 sialic-acid residues show enhance binding prop-
erties and efficiently suppress the haemo-agglutination of
erythrocytes.
A surface engineering strategy was also on the basis of
Jevprasesphant et al. [188] work to improve the properties
of dendrimers. It was found that conjugation of cationic
PAMAM dendrimers with lauroyl chloride decreased their
cytotoxicity and increased their permeation through Caco-
2 cell monolayers. Another study [176] demonstrated that
when the tripeptide Arg-Gly-Asp (RGD) was conjugated
to PAMAM dendrimers (G4), these were less potent in
causing embryo toxicity as compared to non-conjugated
dendrimers.
Dendronized polymers can display a higher loading
capacity and allow the bulk incorporation of bioactive
molecules of higher molecular weights and of different
chemistry, while maintaining high internalization and
transfection efficiency as compared to conventional den-
drimer (Fig. 4). For example, Kono et al. [189] designed
PEG-modified dendrimers having a shell of hydropho-
bic amino acid residues in the peripheral moiety of
the dendrimer to increase their encapsulation ability.
l-phenylalanine or "-benzyl-l-glutamate residues were
introduced to all chain ends of fourth-generation PAMAM
dendrimers, and then PEG (Mw 2000) chainswere attached
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Fig. 5. Photos of dendrons and figurative representation of nature’s architecture and controlled-release strategy (top). Schematic representation of the
step-wise (A→C) degradation of dendronized polymers, from periphery to core (bottom).
to theaminoacid residues. Resultshave shownthat the sur-
face engineering of the PAMAM dendrimers improved the
binding of Rose Bengal guestmolecules than thedendrimer
without the external layer.
Dendritic polymers offer an interesting possibility as
complexing agents for enhanced transdermal delivery
of hydrophobic drugs [105]. Several dendrimers have
shown solubility enhancement of drugs such as dexam-
ethasone (Dex), nifedipine, camphotecin, quinolones and
indomethacin that are hydrophobic or not very soluble
in water [93,105,190,191]. Other studies [192,193] have
also demonstrated the ability of PAMAM dendrimers to
enhance the solubility of non-steroidal anti-inflammatory
drugs (NSAIDs), such as naproxen, ketoprofen, ibuprofen
and diflunisal.
The existence of inner cavities with different architec-
tures in the dendrimers can be used to design controlled
delivery systems [194], where the drug pharmacokinetics
can bemodulated as desired [81,105,195,196]. The interior
of the dendrimers needs to be hydrophobic so that a drug
canbe loaded. Theexterior of thedendrimer, however, usu-
ally needs to be hydrophilic to improve the bioavailability
in the body [81]. Factors such as the ionization state of the
drug have also been reported to affect the release of drug
from PAMAM dendrimers [197].
On the other hand, high drug-loading influences the
water solubility of the product and the biodistribution of
the conjugates [198]. Agashe et al. [199] have studied the
biodistribution pattern of the PPI dendrimer-based car-
bohydrate (mannose and lactose)-coated glycodendrimers
(G5) in mice, in order to explore the potential of these sys-
tems as drug carriers. These complexes were found to be
stable both in vitro and in vivo. All systems were cleared
rapidly from circulation. Moreover, clearance of mannose-
coated PPI dendrimer and lactose-coated PPI dendrimer
was faster than with PPI alone. All complexes accumulated
in liver, but only those with terminal carbohydrate moi-
eties were retained for a longer period of time, which was
related to lectin–carbohydrate interactions. This informa-
tion is significant since it serves as a useful platform in
designing carbohydrate-coated dendrimers for the deliv-
ery of bioactive agents to liver.
The attraction of dendronized polymers as DDS arises
from the possibility to control and refine drug delivery.
Actually, they can allow a temporally controlled delivery
of single or multiple compounds, since step-wise degrada-
tion can be achieved due to the variety of chemical linkages
within their structure (Fig. 5).
Response to a specified stimulus is a fundamental
process of living systems. Learning from nature-inspired
scientists to develop materials that respond to exter-
nal stimuli such as temperature, pH, light, electric field,
chemicals and ionic strength [200]. Thus, smart or stimuli-
responsive polymers respond to specific changes in their
environment and as a consequence dramatic changes in
their physical properties occurs (e.g., shape, surface char-
acteristics, solubility, formation of an intricate molecular
self-assembly or a sol-to-gel transition). The versatility of
smart polymeric materials makes them one of the most
appealing interfaces of chemistry and biology. Dendrimers’
degradation leading to complete depolymerization may
be initiated by reactions at either the periphery or the
core, the so-called self-immolative dendrimers [201–204].
Hiu et al. [205] reported a dendritic PAMAM core (G3)
and poly(N,N-dimethylaminoethyl methacrylate) (PDMA)
synthesized via an atom transfer radical polymerization
(ATRP), the so-called G3-PAMAM-g-PDMA. Chlorambucil
(CLB), an anti-cancer drug was used as a model drug. Con-
trolled drug release from polymers with different average
graft lengths of PDMA was investigated by UV spec-
troscopy. Results showed that the rate of the drug release
could be controlled by pH; the release of CLB from the den-
drimer derivative was faster at pH 1.4 than at pH 10.0.
Moreover, the release of CLB from G3-PAMAM-g-PDMA
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was apparently slower than that from CLB incorporated
into the PAMAM dendrimer. In addition, these studies
also showed that G3-PAMAM-g-PDMA presented a typical
thermo-responsive character.
Pistolis et al. [206] reported that amine-terminated
diaminobutane PPI dendrimers (DAB-32 or DAB-64) were
pH-sensitive controlled-release systems. As a model sys-
tem, pyrenewas incorporated into PPI dendrimers. Release
studies revealed that pyrene incorporation is favored in
basic environments and mainly close to the core of PPI
dendrimers, while its release is induced in acidic media.
Zheng and Pan [207] synthesized dendrimer-star
poly(N-isopropylacrylamide) (PNIPAAM) polymers
with narrow molecular weight distribution using a
dithiobenzoate-terminated PPI dendrimer (G2 and G3)
via a reversible addition-fragmentation transfer (RAFT).
The aqueous solution of the dendrimer-star PNIPAAM
was found to be thermo-sensitive, with a lower critical
solution temperature (LCST) around 32 ◦C. Thus, the use
of methacrylic acid along with NIPAAM, not only induces
changes in the LCST, but also providesmaterials responsive
to both temperature and pH.
pH and temperature-activated polymers are known
to be successful drug delivery systems. Photochemical-
internalization (PCI) can facilitate site-specific delivery,
e.g., escape of the macromolecules from endocytic vesi-
cles into the cytosol. Lai et al. [208] conjugated doxorubicin
(Dox) to PAMAM dendrimers via pH-sensitive and insen-
sitive linkers, acid-labile hydrazone linkages (PAMAM-
hyd-Dox) and amide (PAMAM-amide-Dox), respectively.
They combined doxorubicin-dendrimerswith different PCI
strategies to evaluate the cytotoxic effects. Results showed
that both PCI strategies promoted the PAMAM-amide-Dox
cytosolic distribution, but significantly enhanced the cyto-
toxicity of freeDoxonhumangingival cancer (Ca9-22) cells
at higher concentrations. The authors failed to develop a
multi-modality cancer treatment, but their data provided
insights onpossible researchdirections, namely theneed to
exploit spacers other than amide-linkage in drug-polymer
complexes.
Papagiannaros et al. [209] have screened the cytotoxic
of Dox-PAMAM dendrimer complex attached to liposomes
using different human cancer-cell lines (e.g., lung, colon,
breast, central nervous system and prostate). In this
innovative work Dox was incorporated into PAMAM
dendrimers (3:1 molar ratio) (1) with an efficiency of 97%,
and the anti-cancer activity investigated. Dox-PAMAM
complex was also attached to hexadecylphospho-
choline:eggphosphatidylcholine:stearylamine 10:10:0.1
(molar ratio) (2) andeggphosphatidylcholine:stearylamine
10:0.1 (molar ratio) (3) liposomes, with incorporation
efficiencies of 91 and 95%, respectively. The in vitro
cytotoxicity tests revealed that Dox-PAMAM dendrimers
retained high growth inhibiting activity, which was
decreased when the complex attached to liposome 3. The
activity of Dox was enhanced when hexadecylphospho-
choline was incorporated to liposomal formulation (2).
Formulation 2 was superior among the three formulations
against all cell lines tested. The dendrimeric liposomal
formulation enhanced the activity of Dox against one type
of breast cells. The most sensitive cell lines were those
originated from lung cancer, suggesting a selective action
of Dox as compared to the rest of the cell lines. These
were the encouraging and promising data, showing that
dendrimeric liposomal formulations may be a valuable
strategy for the superior performance of DDS aimed at
treat several types of cancer.
Wiwattanapatapee et al. [210] investigated the use
of dendrimers for colon-specific drug delivery applica-
tions. In their studies, 5-aminosalicylic acid (5-ASA) was
bound to thewater-solubledendrimerusingdifferent spac-
ers containing azo-bond (e.g., p-aminobenzoic acid, PABA
and p-aminohippuric acid, PAH). PAH provide the poly-
mer conjugates a higher loading capacity (3 times) for
5-ASA as compared to that of dendrimer conjugates with
PABA as the spacer. In vitro studies of rats with cecal con-
tent were carried out to investigate drug release from
dendrimer conjugates. The release of 5-ASA fromboth con-
jugates was significantly slower as compared to that of
sulfasalazine (SA), a commercial prodrug. Moreover, the
conjugate with PAH linker showed significantly higher
amount of initial drug release than the conjugate with the
PABA linker. As a consequence, the amount of drug released
from PAMAM-PAH-SAwas significantly higher than that of
PAMAM-PABA-SA conjugate. This study nicely illustrated
the potential use of PAMAM dendrimer for colon-specific
drug delivery, and the important role of the spacers for the
optimization of drug release.
Ghorai et al. [211] have described the first molecules of
anthracene capped chiral dendrimers derived from a 1,3,5-
trisubstituted aromatic core and carbohydrate units in the
interior and periphery. These are claimed to be suitable
for anchoring other useful functionalities aimed at appli-
cations as DDS and light harvesting materials.
It is known that carbohydrate substructures of cell-
surface glycoconjugates constitute important binding
sites for pathogen infection. Dendrimeric systems for
use in a lectin-binding assays have been developed
[212]. Mannose receptors are present in the surface of
monocyte/macrophages (Mo/Mac), alveolar macrophages,
astrocytes in brain, and hepatocytes in liver. For exam-
ple, targeting of anti-retroviral drugs to macrophages,
which in turn are the target cells for HIV, could be an
attractive approach in improving the therapeutic effi-
cacy and reducing the toxicity of anti-retroviral drugs. In
this context, Dutta and Jain [121] explored the target-
ing potential and anti-HIV activity of lamivudine (3TC,
anti-retroviral drug) loadedmannosylatedfifth-generation
poly(propyleneimine) dendrimers (MPPI). The entrapment
efficiencies of 3TC loaded MPPI and PPI dendrimers (G5)
were found to be ∼43 and ∼36%, respectively. The in
vitro release profile showed that mannose-modified PPI
slows drug release as compared to that of unmodified PPI
dendrimers. The results of in vitro internalization studies
showed significant increase in lymphoblast humanT (MT2)
cells uptake of 3TC when MPPI was used, as compared to
that for PPI and free drug. This result is evidence that MPPI
interacts with the lectin receptors present on the surface
of MT2 cells leading to its enhanced cellular uptake. Anti-
retroviral activity was determined using MT2 cell lines by
estimatingp24antigenbyELISA, awidely acceptedmethod
of quantifying the viral load in HIV infection. 3TC loaded
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PPI and MPPI formulations were found to possess higher
anti-HIV, mainly due to the enhanced cellular uptake of
3TC. These data suggest that the proposedMPPI drug deliv-
ery carrier has great potential to increase the efficacy and
reduce the toxicity of anti-retroviral therapy.
Tuftsin, a natural macrophage activator tetrapeptide
with Thr-Lys-Pro-Arg components, presents a broad spec-
trum of activities and binds to several cells of immune
system. For example, Dutta et al. [120] synthesized tuftsin-
conjugated-PPI dendrimers (G5) for targeting to circulating
Mo/Mac. These systems proved to hold potential for the
controlled and targeted delivery of anti-retroviral drugs.
Tuftsin-conjugated-PPI stimulated the phagocytic activity
of the Mo/Mac, especially in HIV infected cells, contribut-
ing to the anti-HIV activity of the drug due to its inherent
anti-retroviral activity. These materials were also found to
be non-cytotoxic, in vivo [186].
Research on dendrimeric-based artificial virus recep-
tors has attracted great deal of attention. Yamada et al.
[213] successfully synthesized a novel class of carbosilane
dendrimer periphery-functionalized lacto-N-neotetraose,
aimed to mimic dengue virus receptor. In another work
[212], they synthesized carbosilane dendrimers periphery-
functionalized with lactotriaose (GlcNAc#1-3Gal#1-4Glc)
with valencies of three, four, six, and 12 for use in a lectin-
binding assay. The hexavalent glycodendrimer showed
a 2500-fold larger binding effect than that of free lac-
totriaose, though the dodecavalent one exhibited only
a 1200-fold larger binding effect. The same group also
reported [214] on the potential of carbosilane dendrimers
periphery-functionalized with galabiose (three, four, and
six galabiose residues) for use as artificial inhibitors
against Shiga toxins. Bhadra et al. [215] synthesized PPI
dendrimers-coated with galactose and investigated the
efficiency on delivering primaquine phosphate (PP, a liver
schizonticide) directly to liver cells. The results showed
that the coating of PPI systems with galactose increases
the drug entrapment efficiency, prolonged circulation
and drug release as compared to uncoated PPI delivery
systems. Agrawal et al. [216] demonstrated a method
to synthesize galactose-coated PLL dendrimers having
polyethyleneglycol (PEG-1000) as core. This method con-
sisted on alternating protection and deprotection steps
of l-lysine by di-tert-butyl dicarbonate (di-BOC) until the
formation of peptide dendrimer (G4) took place. More-
over, they successfully loaded these macromolecules with
chloroquine phosphate, which is extensively employed for
the suppression and treatment of malaria. The internal-
ization studies of uncoated and coated drug dendrimer
formulations in macrophages revealed almost 5 times
reduced phagocytosis due to galactose coating. Galactose-
coated peptide dendrimers drastically reduced haemolytic
activity compared to uncoated PLL formulation. Haema-
tological data suggested that galactose-coating strategy
decrease immunogenicity as compared to uncoated formu-
lations.
Carbosilanes bearing saccharide residues on their sur-
face were first introduced by Matsuoka et al. [217]. An
innovative work [218], described the synthesis of glyco-
dendrimer via carbosiloxane formation. In this work, a
hydrosilylation routewas described to attach carbohydrate
derivatives to carbosilane backbones without using any
hetero atoms.
Prieto et al. [219] investigated the cytotoxicity of
sulfadiazine complexed with fourth-generation PAMAM
dendrimers. Cell culture studies using fibroblasts (Vero
cells) and macrophages (J-774 cells) revealed that the
dendrimeric sulfadiazine complexes did not affect mem-
brane integrity at low concentrations (0.03!M).Moreover,
cytotoxicity tests using human intestinal adenocarcinoma
cell line (Caco-2 cells) showed that dendrimeric sulfadi-
azine did not reduce viability of Caco-2 cells over the
tested concentrations as compared to that for PAMAM(G4).
Remarkably, the in vivo study has shown that brain and
muscle of Wistar rats are the main targets of intravenous
administration of dendrimeric sulfadiazine, which can be
advantageous for drug delivery applications directed to
central nervous system.
For efficient encapsulation and delivery of 5-
fluorouracil (anti-cancer drug), Bhadra et al. [220]
also exploit the surfacemodification route of PAMAMden-
drimers with PEG. PEGylation of the systems was found
to increase the drug-loading capacity of the nanocarrier,
reduce the drug release rate and haemolytic toxicity.
In another work [221], PEGylated PPI (G5) dendrimers
were developed for sustained delivery of famotidine, a H2
receptor antagonist. In vivo investigations demonstrated a
marked difference in the percentage of drug distribution
from the bound drug through PEGylated dendrimer when
compared with the free drug. Similar studies were carried
out by Haba et al. [222]. They have prepared biocompatible
nanocapsules consisting of a PAMAM dendrimer (G4)
having both a PEG chain and a methacryloyl group at
every chain end of the dendrimer through an l-lysine
residue. These studies support previous findings showing
that PEGylation can increase circulation time, provide
sustained release of therapeutic molecules and improve
haemocompatibility. Recently, Kono et al. [223] provided
deeper insights on the designing of dendrimer-based
carriers for accurate drug delivery. They have developed
PAMAM dendrimers (G4) that have a glutamic acid (Glu)
residue at every chain end of the dendrimer. Then, to
obtain PEG-modified dendrimers with sites for conjuga-
tion, PEG chains were attached to amino groups of Glu
residues. Dox was linked to side chains of the Glu residues
by an amide bond, [PEG-Glu(Dox)-G4], or hydrazone bond,
[PEG-Glu(NHN-Dox)-G4]. The developed systems were
stable under physiological conditions, and Dox molecules
were released from PEG-modified dendrimers in acidic
environments such as those of endosomes/lysosomes. The
Dox-bearing dendrimers showed much lower toxicity to
HeLa cells as compared to free drug. However, it was evi-
dent that the conjugates with hydrazone bonds exhibited
higher cytotoxic effects than those with amide bonds.
These results suggest the importance of pH-sensitive
hydrazone linkage for high cytotoxicity. Furthermore,
the PEG-modified dendrimers exhibited a similar level of
toxicity to that of Dox-resistant (SBC-3/ADR100) cells and
their parent Dox-sensitive SBC-3 cells.
Early studies have been performed with peptide den-
drimers andother peptide-bindingdendrimers, to evaluate
peptide–protein and protein–protein interactions. These
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showed that dendrimer-based research can be a valuable
tool for elucidating these processes. For example, Tam
[111] proposed peptide dendrimers to act as immunogens,
also known as multiple antigen peptides (MAPs).
CD derivatives bearing peptides may be useful as
carriers for transporting drugs to biological targets
containing specific peptide receptors. Thus, peptide bio-
recognizability togetherwith theCDhost–guest complexa-
tion properties makes such systems suitable templates for
the application in site-specific drug delivery. Much effort
hasbeenmade to complex lowgenerationdendrimerswith
other polymers. For example, Dodziuk et al. [224] reported
attempts to complex a first-generation dendrimer having
four branches with $-, #- or "-cyclodextrins, found to be
unsuccessful in their subsequent NMR studies.Muhanna et
al. [225] reported a different strategy, with the synthesis of
tetradecavalent amino acid and peptide dendrimers based
on a #-CD core. These were found to have great poten-
tial for application in MAP concept as a means to increase
the peptide–receptor binding, and hence improve the site
specificity of the drug delivery system. Imae et al. [226]
investigated the binding of PAMAM dendrimer to sodium
hyaluronate (NaHA). They successfully synthesized the
PAMAM/NaHA complexes.Moreover, static light scattering
data showed that when the dendrimers bind to the NaHA
chain, the wormlike character of NaHA is scarcely changed
at low [NH2]/[COO−] ratios. However, the structure of
NaHA changed to a rod-like one at high [NH2]/[COO−] val-
ues, where the terminal numbers of dendrimers exceed at
leastfive times the repeatingunit numbersof aNaHAchain.
They postulated that electrostatic interaction is essential,
but not sufficient to connect such large numbers of den-
drimers to NaHA because the number of amino terminal
groups is 42 times larger than the number of carboxy-
lates. They concluded that hydrogen-bonding interaction,
besides the electrostatic interaction, should play an impor-
tant role in the formation of these complexes. For rational
design of intracellular nanocarriers, it is important to
better understand the transport mechanisms across bio-
logical barriers. In general transport of nanosystems is
dependent on one hand, on their nature, including their
location, function and permeability, and on the other, on
the nature of the nanocarrier molecules (e.g., molecular
weight, charge, hydrophobicity, flexibility) and geometry
[227]. Fig. 6 shows a simplified representation of the endo-
cytic route of nanoparticle aimed at act as intracellular
reservoir of drugs. Ultimately, these are expected to be
released inside the cells and bothmodulate and control the
cell machinery.
Recently, Perumal et al. [228] investigated the effect of
surface functionality on cellular trafficking of dendrimers.
In this report, different dendrimers (G4 OH-terminated,
G4 amine-terminated and G3.5) were firstly, labeled with
FITC. Results revealed that dendrimers are internalized by
human lung carcinoma epithelial cells (A549 cell line).
Using inhibitory drugs (e.g., sucrose, chlorpromazine, fil-
ipin, nocodazole and cytochalasins) for endocytosis, they
found that nanoparticles uptake is mainly by fluid-phase
endocytosis, independently of the external functionality,
but significant differences in uptake mechanisms were
seen. For example, anionic dendrimers appear to bemainly
Fig. 6. Simplified representations of a nanoparticles intracellular reser-
voir for the sustained release of drugs aimed at modulate the cell
machinery. (1) Internalization contact and crossing of the cell membrane;
(2)uptakeof thevector complex into intracellular endosome; (3)nanopar-
ticles release from the endosome into cytoplasm; (4) sustained drug
release and interaction with the intracellular receptor release from the
endosome into the cytoplasm; (5) activation of cellsmachinery or translo-
cationof the complex receptor/drug into thenucleus; (6) gene expression:
mRNA transcription and protein translation from mRNA.
internalized by caveolae mediated endocytosis in A549
lung epithelial cells, while there was evidence of cationic
and neutral dendrimers internalization by a non-clathrin,
non-caveolae mediated mechanism that may be by elec-
trostatic interactions or other non-specific fluid-phase
endocytosis. Confocal microscopy studies revealed that
cationic dendrimers were mostly localized in the endo-
somes in the cell periphery, with both anionic and neutral
dendrimers found to localize in the lysosomes. These
data showed that the surface charge of the dendrimers
strongly influences their uptake by cells and intracellular
localization, thus opening up new possibilities of tar-
geting therapeutic agents to subcellular organelles. Pisal
et al. [229] investigated the permeability of arginine-
and ornithine-conjugated PAMAM dendrimers (G4) across
Caco-2 cell monolayers. Conjugates were obtained by link-
ing the polyamines to the amine groups of the PAMAM
dendrimers (G4) using an Fmoc synthetic route, and then
the conjugates were labeled with fluorescein isothio-
cyanate (FITC). The in vitro cell culture studies revealed
that surface-modification of dendrimers increase perme-
ability. Although themechanismsbywhich thepolyamines
improve the permeation of the dendrimers remain unclear,
the authors speculated that disruption of intercellular tight
junctions could provide a possible mechanism. Similarly,
Seib et al. [230] reported on the endocytic properties and
intracellular trafficking of both linear and branched PEIs,
and cationic PAMAM dendrimers (G2-4) in B16F10murine
melanoma cells. All polymers were first conjugated to Ore-
gon Green (OG) and carefully characterized for pH- and
concentration-dependence fluorescence. Flow cytometry
studies revealed that uptake rate for PAMAM (G4) was the
highest, followed by branched PEI, linear PEI, PAMAM (G3)
andat last PAMAM(G2). Cellswere cultured in thepresence
of the dendrimers and chlorpromazine or wortmannin to
assess themechanisms of uptake. The precise mechanisms
of PAMAM internalization were once not totally clarified,
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but the authors suggest that PAMAM (G4) internalization
can be cholesterol-dependent.
When compared to traditional macromolecular archi-
tectures (e.g., linear, cross-linked, branched), the unique
features of the dendrimers and dendrimeric systems can
improve the cellular uptake, bioavailability of therapeutic
molecules inside the cells for long time periods, and conse-
quently decrease the dosage and frequent re-dosage needs.
There is a need to intensify the comprehensive research
on the mechanisms of cellular uptake to develop safer and
even more efficient dendrimeric nanocarriers.
3.2. Tissue engineering (TE) applications of dendrimers
and dendronized polymers
In the recent years, great advances have appeared in the
emerging field of TE and regenerative medicine, affording
the opportunity for this review of recent achievements and
scientific considerations on the subject.
In the early 1990s, Langer and Vacanti [231] coined
TE to indicate “an interdisciplinary field of research that
applies the principles of engineering and the life sciences
towards the development of biological substitutes that
restore, maintain, or improve tissue function”. This con-
cept is basedonunderstandingof how tissue formation and
regeneration occur, and instead of traditional implantation
of new spare parts it envisions the use of new functional
tissues. To accomplish this goal, three main therapeutic
strategies have been proposed [232]: (i) implantation at
injury site of freshly isolated cells (e.g., ownpatient cells) or
cultured cells (differentiated cells alone or in combination
with stemcells, for example); (ii) in situ tissue regeneration,
e.g., implantation of a scaffold at the diseased/damaged
tissue aimed at promote healing/repair by the patient’s
own cells; and (iii) implantation of tissues obtained from
combining cells and scaffolds that are cultured in vitro
with or without the presence of bioactive molecules. Thus,
the basic TE triad consists of cells, scaffolds and bioactive
agents, which can be used separately or in combination.
Regenerativemedicine uses the cell and tissue engineering
principles for the regeneration of damaged/diseased body
tissues.
The use of dendrimers’ architectures in cells and TE
applications is still in its infancy. A fewexamples have been
reported, and these are mainly related with applications
in cell-adhesion studies as nanopatterning [233]. Interest-
ingly, ligand-modified dendrimers have been proposed for
use as substratum for cell culture and high performance
bioartificial organs [234].
On the other hand, it has been reported [88] that when
a dendrimer reaches a certain generation (a variable factor
according to the dendritic structure, but in general equal
to or greater than G4), important conformational change
occurs and the structure assumes a densely packed globu-
lar shape. Several authors [80,88,235] have discussed the
potential of tuning dendrimers to developmacromolecules
that can mimic globular proteins. In fact, partial core
shell-filled tecto(dendrimers) can be obtained by cova-
lently assembling PAMAM dendrimers (nucleophilic or
electrophilic) around other electrophilic or nucleophilic
core dendrimers [236]. This feature allowsmany new tech-
nological applications. One possibility is to take advantage
of dendrimer architecture towards resembling the role of
different proteins in the cells culture media. For example,
dendrimers may be a valuable tool for the development of
synthetic serum-free culture media and adequate substra-
tum for superior cell culturing. Fluorescence spectroscopy,
differential scanning calorimetry and fluorescent-probes
studies [237,238] showed that dendrimers interact with
proteins giving rise to stable complexes by establishing
both electrostatic and non-electrostatic interactions.
Kim et al. [239] also investigated the response of
human epithelial cells to dendrimer-immobilized sub-
strates, with or without D-glucose displayed as a terminal
ligand. When the topographic surface possessed a rough-
ness of 4nm, epithelial cells cultured on naked dendrimer
surface without D-glucose were somewhat stretched in
their morphology compared with those on a non-modified
plain surface. However, for the roughness values higher
than 4nm cell stretching was inhibited, thus result-
ing in the predominance of round-shaped cells. The
change in cell morphology was quite evident on the sur-
faces with D-glucose-displayed dendrimers. Fluorescence
microscopic observation showed that when the roughness
value increasedup to 4.5nmon these surfaces, an enhance-
ment of cell stretching occurs. These results suggested that
surface roughness and D-glucose display induce changes
in cellular morphology caused by the cytoskeleton forma-
tion accompanied by marked cell elongation. Therefore,
this study demonstrated that dendrimer surfaces can offer
a promising design for optimizing cells culture conditions.
Benhabbouret al. [240], demonstrated that cells showed
a greater affinity for the dendronized surfaces as compared
toAu surfaces (control).Moreover, in vitro cell culture stud-
ieswithmouse3T3fibroblasts showed that cell attachment
was diminished for the PEG-grafted Au surfaces as com-
pared to the control Au and G1–G4 dendronized surfaces.
These results showed thatdendronized surfacespresenting
a large number of hydroxyl groups can be a reliable alter-
native to the use of peptides to promote cell-adhesion and
proliferation.
3.2.1. Bone TE
Bone is a very dense and specialized form of connec-
tive tissue, highly specialized in the several regions that
constitutes it and acts as a support for the body. Bone
lesions above a critical-sized segmental defect still remain
a huge challenge to reconstructive surgery and regenera-
tivemedicine. This is mainly due to the fact that bone has a
limited ability to heal [241,242]. Inmany clinical situations
there is the need for a surgical intervention and the use
of autografts [243,244], allografts or xenografts [244,245]
transplantation. Still, the preferred clinical strategy is an
autologous transplantation, since it avoids the problem of
immune rejection [246] and consequent administration of
drugs for immunosupression of the host [247]. Currently
available treatmentpossibilities are far fromaffording truly
ideal solutions. Recently, TEprinciples havebeen applied to
this problem, e.g., by seeding bonemarrow stem cells onto
scaffolds (constructs) [248] or prostheses [249] to recreate
a regenerative environment at the defect area and achieve
a superior bone healing. Despite important advances, the
J.M. Oliveira et al. / Progress in Polymer Science 35 (2010) 1163–1194 1177
Fig. 7. Fluorescence microscopy image of the RBMSCs cultured in the
presenceof FITC-labeledCMCht/PAMAMdendrimernanoparticles (green)
for seven days. Nuclear DNA and cytoskeleton were labeled with Hoechst
33258 (blue) and Texas-Red phalloidin (red), respectively. (For interpre-
tation of the references to color in this figure legend, the reader is referred
to the web version of the article.).
performance of constructs remains limited, in part due to
the need of optimized cell culture techniques [250]. To cir-
cumvent these limitations substantical efforts are focused
on developing novel nanocarriers aimed at modulate cells
behavior. Previously, our group [183] investigated Dex-
loaded CMCht/PAMAM dendrimer nanoparticles for their
potential role in the regulation of osteogenesis, in vitro.
That study focusedon theuptakeefficiencyandmechanism
of FITC-labeled CMCht/PAMAM dendrimer nanoparticles
using rat bone marrow stromal cells (RBMSCs). Fluores-
cence microscopy studies revealed that the developed
nanocarriers could be efficiently internalized by RBMSCs,
after a few hours (Fig. 7).
Flow cytometry studies revealed that RBMSCs cultured
in the presence of colchicine, an endocytotic inhibitor,
reduce the internalization of the nanoparticles. These data
showed that uptake by cells was primarily via an active
endocytosis mechanism, but not exclusively. Moreover,
the biochemical data demonstrated that the Dex-loaded
CMCht/PAMAM dendrimer nanoparticles were not cyto-
toxic and promote osteogenesis (2-D system). Recent
studies [251,252] have shown that combination of hydrox-
yapatite (HAp) scaffolds, bone marrow stromal cells and
Dex-loaded CMCht/PAMAMdendrimer enhanced osteoge-
nesis in vitro (3-D systems), and de novo bone formation as
compared to controls, in vivo (Fig. 8). Remarkably, animal
studies showed that the novel Dex-loaded CMCht/PAMAM
dendrimer nanoparticles may be beneficial as intracellular
nanocarriers, supplyingDex in a regimentedmanner,while
avoiding theneedof culturing the cells in vitro for longperi-
ods of time. Moreover, this strategy facilitates modulation
anddirect stemcells differentiation towards theosteogenic
phenotype, to enhance in vivo proteoglycan ECM synthesis
and de novo bone formation.
Dendritic monomers have also been studied as com-
ponents in dentistry applications, to allow polymerization
to extend further, as incomplete polymerized matrixes
can cause irritation, allergy or toxicological effects [253].
Fig. 8. Light microscopy photographs of the HAp-RBMSCs implant sec-
tion (decalcified), stained with haematoxylin and eosin after 4 weeks of
subcutaneous implantation: HAp scaffold seeded with 1×106 RBMSCs
thatwere expanded in vitro (7 days), inMEMmedium supplementedwith
0.01mgmL−1 Dex-loaded CMCht/PAMAMdendrimer nanoparticles, prior
implantation. It is possible toobserve representative areasof theHApscaf-
fold (S),denovobone formation (NB), fibrous tissue (F). Blackarrows reveal
the cells lining, which is suggestive of active osteoblasts. Osteocytes can
also be visualized (*).
In fact, photopolymerized dendritic copolymers and par-
ticulate filler composites have been combined for use as
dental restorative materials [254]. In that study, dendritic
monomers were found to enhance the copolymerization
of methyl methacrylate and to lower the viscosity, which
canbe advantageous to improve thebiocompatibility of the
fillers.
3.2.2. Cartilage TE
Two main types of cartilage are found in the human
body, namely the “unstressed” and “stressed” cartilage,
in ear and joints, respectively. The general features of
cartilage tissue include: (i) a small number of chondro-
cytes (less than 10% of the weight of articular cartilage)
with low proliferation rate and having both catabolic and
anabolic functions; (ii) a high content of water (75% of
the wet weight of articular cartilage); (iii) an abundant
ECM composed by proteoglycan and different types of
collagens (mainly type II), corresponding to 15–30 and
50–73% of the solid ECM weight, respectively; (iv) the
absence of nerve and vascular systems [255,256]. Although
a classical wound healing response is initiated, articular
cartilage lesions are repaired without complete restora-
tion of the component and architecture of the native tissue.
This occurs since in the avascular tissue regenerative cells
cannot migrate to the defect void unless the lesion goes
beyond the subchondral bone plate [257,258]. Therefore,
a regenerative response will be only possible when it is
provided an artificial access by the marrow [259]. This
consideration underlies several clinical strategies that are
currently employed in the treatment of small cartilage
lesions namely, the subchondral abrasion, Pridie’s perfora-
tions,micro-fracture, and transplantation of osteochondral
plugs [258,260–262]. Although, in most cases after clinical
intervention the repaired tissue tends to degenerate, with
the formation of undesired fibrocartilage [257,263,264].
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Many attempts have been made to develop biomaterials
for cartilage repair/regeneration. A few have exploited the
advantages of dendrimers for this type of applications.
Sontjens et al. [265] synthesized a photo-crosslinkable
hydrogel scaffold for cartilage repair based on a triblock
copolymer consisting of PEG core and methacrylated-
poly(glycerol-succinic acid) (PLGSA) terminal blocks. In
vitro chondrocyte encapsulation studies demonstrated
that the developed hydrogels supported the synthesis
of proteoglycans and type II collagen, which denotes
cartilaginous extracellular matrix formation. Moreover,
encapsulated chondrocytes showed no signs of dedifferen-
tiation. Despite the promising results in vitro, the authors
discussed the need to improve mechanical properties and
tailor the degradation rate of the developed hydrogels to
obtain superior performance of the hydrogels, in vivo.
3.2.3. Ocular wounds
Another example of dendrimer applications in TE is
related to attempts to improve the biological response of
different biomaterials. In one study [43], laminin-based
peptide YIGSR was introduced into a dendrimer-collagen
hydrogel by linking the peptide to the residual dendrimer
amine groups. The incorporated YIGSR peptide promoted
the adhesion andproliferationof the corneal epithelial cells
cultures onto the collagen hydrogel, in vitro. Moreover,
neurite extension and nerve cell densitywere enhanced on
thesematerials relative to unmodified gels or controls. This
work is anunprecedented example of the ability to tune the
biological function through the dendrimer crosslinker, and
a new strategy towards obtaining polymer-based tissue
engineering scaffolds with improved biological perfor-
mance.
Inspired by the functional significance of collagen in
nature and its remarkable physiological roles, Khew et al.
[266] have developed the so-called enzymatically cross-
linked collagen-mimetic dendrimers. These were obtained
in a two-step procedure: (i) collagen-mimetic peptides
supplemented with a cell-binding sequence (GFOGER)
and enzyme-specific cross-linking domains (EDGFFKI and
APQQEA) were conjugated onto a PAMAMdendrimer (G2),
resulting in a crosslinkable collagen-mimetic dendrimer,
and (ii) enzyme-mediated cross-linking the different
collagen-mimetic dendrimers by tissue transglutaminase.
Collagen-mimetic dendrimers were first assessed for their
cytotoxicity, and then adhesion studies were carried out
using L929 mouse fibroblasts and a hepatoma cell line
(Hep3B cells), respectively. Results were indicative of the
non-cytotoxic natureof thepolymers. The adhesion studies
have proven that enzymatic protein cross-linking, which
is a common physiological event in the extracellular envi-
ronment, can significantly improve cell-adhesion on the
novel collagen-like biomaterial. Moreover, it was observed
that combining collagen-like structural domain and bio-
logically relevant epitopes (e.g., cell-binding sequence
and enzyme-substrates) into a molecular design of a
biomimetic collagen could be a promising approach for
mimicking more closely its biological function.
The repair ofwounds after traumatic or surgical injury is
of significant clinical and research importance. For exam-
ple, corneal wounds arise from surgical procedures (e.g.,
transplants, incisions for cataract removal and intraocu-
lar lens implantation, laser-assisted in situ keratomileusis),
infections (ulcers), and traumatic injury (lacerations, per-
forations). Currently, these wounds are repaired using
nylon sutures, but this technique is not ideal because the
suturematerial does not actively participate in healing, and
the procedure is inherently invasive. Therefore, alterna-
tive strategies using adhesive polymers have been tested.
For example, Duan and Sheardown [267] cross-linked col-
lagen with multi-functional dendrimers. PPI octaamine
dendrimers (G2)were used to generate highly cross-linked
collagen hydrogels with mechanical properties that would
make it appropriate for use as a corneal TE scaffold.
For the superior performance of ocular wounds, hydro-
gel adhesives should meet some specific criteria, namely:
(i) adhere to the moist corneal surface and seal the wound
to withstand high intraocular pressures; (ii) possess ade-
quate rheological properties to permit a controlled and
rapid placement; (iii) ability to seal the corneal wound in
a controlled manner and restore the intraocular pressure;
(iv)maintain the structural integrity of the eye and possess
a refractive properties resembling as much as possible to
native cornea; (v) be biocompatible and provide a micro-
bial barrier; and (vi) be biodegraded or bioabsorbed on a
time scale consistent with tissue regeneration.
Grinstaff [268] has developed a set of dendrimeric adhe-
sives composed of dendrimers of different generations (G1,
G2 G3) combined with PEG, glycerol, and succinic acid
for finding application in the repair of corneal wounds.
The polymer was modified to contain terminal methacry-
late (MA) groups, [G1]-PGLSA-MA)2-PEG. Two strategies to
develop the ocular adhesives were explored: (i) the use
of a photo-cross-linking reaction to form the dendrimer-
PGLSA-MA)2-PEG, and (ii) the use of a peptide ligation
reaction to couple the individual dendrimers together to
form the lysine-based dendron with terminal cysteines
adhesive hydrogel G2-(Lys)3-Cys4) and PEG-dialdehyde
(PEG-DA). Both strategies afford hydrogels that are adhe-
sive, transparent, elastic, hydrophilic, and soft. The in
vivo studies in chicken eyes have shown that the photo-
crosslinkable ([G1]-PGLSA-MA)2-PEG adhesive completely
sealed the linear lacerations onpost-operativeday. Thehis-
tological studies demonstrated that wounds sealed with
these adhesive gels appeared to be more complete as
compared to sutured wounds, after 28 days. The dendron
([G2]-(Lys)3-Cys4) and PEG-DA proved to be effective in
the repair of corneal lacerations and required less surgical
time than conventional suturing, ex vivo. The advantage of
photo-cross-linked gels lies on the ability of the polymer
to crosslink and adhere to the tissue where the clinician
directs the light. However, a limitation is the potential risk
of ocular damage when using light. Thus, a cross-linking
strategy based on peptide bonding is attractive since it can
avoid the need for light and the reaction is performed at
neutral pH; thus the polymer can be cross-linked upon
placement on the tissue.
3.2.4. Diagnosis and inflammation
In autograft transplantation, biopsies are performed
harvesting the smallest amount of tissue possible from
patients, to prepare starter cells. Frequently, tissue is lised
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and cells are expanded. During culturing changes in intra-
cellular states can cause variation in individuality in cell
population and behavior. Moreover, due to terminal differ-
entiation cellular senescence can occur. Therefore, there is
the need to investigate the cellular status, prior implan-
tation into the patient. In this context, Hata et al. [269]
proposed a novel image analysis based on the observation
of the partial anchoring of the cells to a glucose-dendrimer-
immobilized culture surface as a mean to evaluate the
formation of the cellular cytoskeleton in a non-invasive
manner. In this study, formation of the cellular cytoskele-
ton was correlated with the growth cellular potential. This
innovative method allowed observation of the cells mor-
phology, andevaluate the regenerativepotential of thecells
for use in TE strategies.
In the last few years, there has been great interest
[270,271] in the mediators responsible for the selective
recruitment and activation of immune cells at inflam-
matory sites. Among these mediators, chemokines have
received particular attention in in vivo studies involv-
ing the investigation of cytokine-associated responses
to biomaterials. Chemokines are a large family of small
(7000–15,000Da, from 67 to 127 amino acids in length),
structurally related heparin-binding proteins, which are
classified into four subfamilies according to the configura-
tion of cysteine residues near the N-terminus, depending
on whether the first two cysteines are separated (CXC,
CX3C) or not (CC, C) by an intervening amino acid [272].
Chemokine messages are decoded by specific receptors
[273–275] that initiate signal transduction events, leading
to a multitude of cellular responses, including chemo-
taxis and activation of inflammatory and bone cells. Thus,
the development of synthetic chemoattractants by link-
ing small peptide sequences that are known to interact
with chemokine receptors to dendrimers and,when appro-
priate, chemokine inhibitors [276] can be envisioned. In
regenerative medicine, the development of dendrimer-
based chemoattractants can find interesting applications
towards recruiting stem cells [277]. This unexploited
area can open up new therapeutic avenues, not only for
treating autoimmune diseases, but also, to be used in
innovative TE strategies, since it can lead to the supe-
rior repair/regeneration of damaged/diseased tissues by
endogenous cells.
3.3. Central nervous system (CNS) applications of
dendrimers and dendronized polymers
In spite of considerable study, the brain and the cen-
tral nervous system (CNS) still encasemanymysteries, and
therefore their pathologies still represent amajor challenge
for biomedical science. Neurodegenerative disorders such
as Parkinson’s or Alzheimer’s disease, stroke, brain tumors
or multiple sclerosis (MS) are among leading debilitating
diseases within our society to which feasible and long last-
ing therapeutic approaches are yet to be found.
The brain is protected from the rest of the body by
structures known as barriers that most often represent
a major hurdle for the delivery of diagnostic and ther-
apeutic agents [278]. In fact most of the systemically
administered drugs do not enter the brain in adequate
amounts, and the attempt to resolve this problem by
increased dosage usually leads to undesirable side effects.
The most well-known barrier is the blood brain barrier
(BBB), which consists of “walls” of capillaries that sepa-
rate the brain from the circulating blood [278]. Its low
permeability is mostly attributed to brain micro-vessel
endothelial (BMVEC) cells which form tight junctions and
have a low pinocytic potential [278–281]. Moreover, the
BBB is also formed by astrocytic processes, leptomeningeal
cells and a parenchymal membrane that together isolate
the brain from unwanted molecules [278]. However, not
all molecules are “unwanted” by the BBB. For instance, the
latter provides for selective transport of small molecules,
lipophilic and lowmolecular weight compounds, polypep-
tides and even cells to the CNS. In particular, nutrients
and endogenous compounds such as amino acids, glucose,
essential fatty acids, vitamins, minerals, and electrolytes
are effectively carried by the BBB. Most of these processes
are based on receptor-mediated endocytosis [279]. For
example, receptors such as insulin, transferrin, endothelial
growth factors, amino acids, glucose (GLUT 1) transporter
are known to be expressed by the BBB [279]. In this sense
the BBB can be seen as regulatory membrane, which selec-
tively allows the passage of essential molecules to the
homeostasis of the CNS, while inhibiting what is believed
to be “harmful” ones. Thus, when designing a strategy
to deliver a therapeutic agent into the CNS one must
understand the properties of the BBB in order to allow an
efficient delivery nanocarrier to the target site(s). Initially
films, tablets, microspheres and intracranial polymeric
materials were tested for these applications. However,
as recently reviewed by Kabanov and Gendelman [278],
such strategies had limited success namely due to their
invasiveness, inflammatory responses to implants and
limited distribution of therapeutic molecules around the
implantation site. It was in this context that nanomedicine
based approaches were put forward as a possible solu-
tion. Within these one can found liposome’s [282,283],
polymeric nanoparticles [284,285], and nanogels [286].
Dendrimers are particularly interesting for applications
mentioned [287]. Surprisingly, their application to the CNS
is also still quite scarce. Nevertheless, some nice examples
can be drawn from the literature of the possible applica-
tions of these systems for drug delivery in the CNS. For
instance Suppatone et al. [288,289] suggested the use of
dendrimers for the removal of prion infection. In a couple of
studies it was reported that branched polyamines, includ-
ing PAMAM, PPI and PEI dendrimers, were able to purge
PrPSc, the protease-resistant isoform of the prion protein,
from scrapie-infected neuroblastoma (ScN2a) cells in cul-
ture. The removal of PrPSc by these compounds depended
mainly on both the concentration of branched polymer
and the duration of exposure. Structure–activity analy-
sis revealed that a high surface density of primary amino
groups was required for polyamines to eliminate PrPSc
effectively from cells. In a subsequent study it was also
demonstrated that exposure of ScN2a cells to 3mgmL−1
of PPI (G4) for four weeks not only reduced PrPSc to a level
undetectable by Western blot, but also eradicated prion
infectivity as determined by bioassays in mice. Moreover
exposure of purified RML prions to branched polyamines
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in vitro disaggregated the prion rods, reduced the #-sheet
content of PrP 27–30, and rendered PrP 27–30 susceptible
to proteolysis.
Cationic phosphorous dendrimers have been proposed
for the same applications, also through inhibition of
fibril assembly [290]. Spectrofluorometric assays with
thioflavin T (ThT) and Fourier transformed infra-red (FTIR)
spectroscopy show that these classes of phosphorous den-
drimerswere able to clearly interferewith the PrP 185–208
aggregation process, both by slowing the formation of
aggregates (by causing a decrease of the nucleation rate)
and by lowering the final amount of amyloid fibrils, a
common hallmark of conformational diseases. In fact,
time-course experiments demonstrated that phosphorus
dendrimers were able to remove quickly existing PrPSc
molecules and the clearance occurred within 4h of treat-
ment [123]. Themechanism behind these actions is mostly
unknown. However, similar towhat happenswith PAMAM
dendrimers, the breakage of oligomers or whole fibrils
caused by dendrimers probably has a strong role on the
observed phenomena. A similar report was put forward
by Klajnert et al. [122] in a study in which PAMAM den-
drimers (G3) were used to control the nucleation rate
of amyloid plaques. The outcome of this study revealed
that dendrimers at low concentrations can modulate the
aggregation process by affecting the nucleation rate. How-
ever, at higher concentrations it seemed that dendrimers
promoted the elongation of nucleation chains. Therefore,
interest in the reported effect of dendrimers has to be
considered within the ongoing search for compounds that
can affect amyloid formation and in relation to the struc-
tural intermediates in this process responsible for cytotoxic
effects. In this sense low dendrimer concentrations could
contribute to a decrease of the lifetime of low molecu-
lar weight intermediates and contribute to decrease the
potential cytotoxic effects of the peptides. For instance
Patel et al. [291] described the use of modified PAMAM
dendrimers for Alzheimer’s disease. In this particular, case
sialic-acid conjugated PAMAM dendrimers using a phys-
iologically relevant attachment of the sialic-acid to the
dendrimeric termini were prepared. Computer-aided EPR
analyses have proved to be a valuable tool to study the
interactions between dendrimers and peptides involved in
Alzheimer’s and prion diseases [292].
Another route to use dendrimers for CNS related appli-
cations, namely for transfection purposes, is by coating
the latter with specific peptides. An example of such an
approachwas presented by Kim and co-workers [293,294],
in which arginine-grafted PAMAM dendrimers were used.
In this case these PAMAM-Arg dendrimers were com-
plexed with expression of both a reporter gene (luciferase
expression plasmid pCN-Luci) and a high mobility group
box 1 (HMGB1) shRNA transgene-expressing plasmid for
gene knock down. Results revealed that these PAMAM-
Arg/DNA complexes showed particularly high transfection
efficiencies and low cytotoxicity in primary cortical cells,
as compared to other gene carriers, such as native PAMAM.
Other classes of dendrimers have also been proposed
for CNS regenerative medicine, such as those based on
polyesters. Dhanikula et al. [194,287] suggested the use of
polyether-copolyester (PEPE) dendrimers conjugated with
d-glucosamine, and loaded with methotrexate (MTX) in
order to allow a better delivery across the BBB. The results
revealed that the efficacy of MTX-loaded dendrimers was
established against U87 MG and U 343 MGa cells (two
glioma cell lines). In vitro studies revealed that gluco-
sylated dendrimers were internalized by endocytosis in
significantly higher amounts than non-glucosylated den-
drimers by both the cell lines. Moreover, the amount of
MTX-transported across an in vitro model of the BBB was
three to five times more after loading in the dendrimers,
which indicates that glucosylation further increased the
cumulative permeation of dendrimers across BBB, and
hence increased the amount of MTX available across it.
This work evaluated a different set of dendrimers, as well
as different strategy, for potential use delivery across the
BBB. However, it should be considered with caution, as
only in vitro models were used, and the in vivo proof
of concept is yet to be demonstrated. A similar strategy
(e.g., cell targeted particles) was followed by Wu et al.
[295], who developed a vehicle for boron neutron cap-
ture therapy (BNTC), instead of MTX. A heavily boronated
PAMAM dendrimer was chemically linked to C225 by
means of the heterobifunctional reagents N-succinimidyl
3-(2-pyridyldithio)-propionate andN-(k-maleimido unde-
canoic acid)-hydrazide. Initial in vitro studies revealed that
the F98EGFR glioma cells mentioned above specifically
internalize the particles when compared to receptor-
negative F98 wild-type cells. Further in vivo studies were
conducted by stereotactically implanting F98EGFR cells
into the brains of Fischer rats. The targeted boronated
dendrimers were administered 14 days after either con-
vectionenhanceddelivery (CED)ordirect intratumoral (i.t.)
injection. Results revealed that not only were the targeted
dendrimers receptor specific in vivo, but also that animals
exposed to the tested therapy displayed higher survival
rated when compared to controls. In this sense it appears
that this strategy for using dendrimers as targeted particles
for therapeutic usage is more favorable than the former.
Another in vitro study [296] described a set of polyester
based dendrimers denoted as PLGSA. Reports regarding
CNS applications are scarce, but it was demonstrated that
these dendrimers could encapsulate camptothecins and
could be internalize by glioblastoma cells (SF-268 cell line).
Another study [297] suggested a possible source of delivery
vehicles based on dendrimers denoted as CMCht/PAMAM
dendrimer nanoparticles. Experiments with post-natal
hippocampal neurons and cortical glial cells revealed
that both cell populations were able to take up the
CMCht/PAMAM dendrimer nanoparticles. The internal-
ization rates changed according to the cell populations,
reaching a maximum peak after 48h of incubation. Overall
astrocytes and microglial cells disclosed higher internal-
ization rates (around 100% of the total cell sub-population)
followed by neurons and oligodendrocytes (up to 80–90%
of the observed cells). Further experiments for periods of
up to seven days revealed that the periodical addition of
CMCht/PAMAM dendrimer nanoparticles was required to
maintain the levels of internalization. Finally, it was also
observed that cell viability and proliferation were not sig-
nificantly affected by the presence of the CMCht/PAMAM
nanoparticles. These resultswere quite promising, but sim-
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ilar to what it was described for other studies described
here, further in vivo proof of concept needs to be done.
3.4. Gene delivery applications of dendrimers and
dendronized polymers
The ability to transfer genetic material efficiently, into
the nucleus and cytoplasm of eukaryotic cells may allow
treatment of a variety of genetic disorders. There are
two types of vectors to gene delivery: (i) viral and (ii)
non-viral. Viral-mediated DNA vehicles (infection) have
played a major role in gene therapeutics. Unfortunately,
initial enthusiasm associated to the high infection yields,
has been tempered by growing concerns regarding safety
issues such as toxicity, immunogenicity and oncogenicity
[298,299]. On the other hand, synthetic DNA delivery sys-
tems “transfection” provide potential alternatives for gene
therapy and DNA vaccination. Major drawback of current
transfection technology is the low efficiency compared to
infection techniques, although new materials and formu-
lations [300–302] are under study.
Genetic material is usually imported into the cell by
endocytosis where, via the endosomes, it can be trans-
ported to lysosomes to other intracellular membrane
compartments or to the cytosol. Thus, they first reach
mildly acidic endosomes (pH 5.0–6.5) and then end up
in lysosomes, where they face much lower pH condi-
tions and possible enzymatic degradation. Therefore, the
importance of transferring geneticmaterial into the cytosol
is an extremely important process in the development
of effective gene therapies. Moreover, transport of the
gene into the nucleus must occur without imparting dam-
age/inactivation from the vehicle itself. This renewed the
interest in pH-responsive dendrimeric nanocarriers as a
mean to enable these macromolecules to reach their sub-
cellular targets.
Dendrimers play a significant role in thedevelopment of
non-viral vectors for gene delivery due to the high charge
density and tunable surface functional groups, thus allow-
ing optimal condensation and formation of nanostructures
with DNA, the so-called “dendriplexes”.
Amine-terminated PAMAM dendrimers (polycationic)
can interact with the negatively charged phosphate groups
of nucleic acids. This ensures consistent formation of trans-
fection complexes. In fact, the transfection reagent called
SuperFect® consisting of activated dendrimers is com-
mercially available. Activated dendrimers can carry higher
amounts of genetic material compared to that of viruses.
SuperFect-DNA complexes are characterized by high sta-
bility, and provide more efficient transport of DNA into
the nucleus than liposomes. It has been proposed that
the high transfection efficiency of dendrimers may not
only be due to their well-defined shape, but may also
by the low pK of the amines (3.9 and 6.9). The low pK
permit the dendrimer to buffer the pH change in the
endosomal–lysosomal compartment. This canbebeneficial
since it can promote polymeric swelling, thus facilitating
the disruption of the organelle membrane, the complex
release or DNA itself. Therefore, they have an intrinsic
endosomolytic escape capacity, or canmediate their escape
bydegradable spacers. Another advantage is that thesevec-
tors can also prevent fast degradation of DNA by endo-
and exo-nucleases. PAMAM and other cationic dendrimers
such as PPI, thus fulfill these requirements. Initial work
by Haensler and Szoka [303] have shown that the three-
dimensional spherical structure of the PAMAMdendrimers
(G5) could be broken by heating and, surprisingly the frac-
tured dendrimers led to significant enhanced transfection
efficiency over naked plasmid DNA. Recently, Kim et al.
[304] have proposed the use of poly(amino ester) obtained
by bulk condensation of two monomers-containing mul-
tiple reacting groups towards obtaining a non-viral and
cationic polymer-based gene delivery system. The particu-
lar feature of this system consisted on the low cytotoxicity
and slow degradation which possibly long-term therapeu-
tic applications.
Many factors affect the efficiency of non-viral gene
delivery systems. For successful gene therapy the genetic
material should be permanently integrated and expressed
by cells. In this context, Galetti et al. [305] demon-
strated that antisense oligonucleotides (ONs, gene-specific
sequences of nucleic acids with 15–25 bases) directed to
LMP1 mRNA, effectively suppressed LMP1 gene expres-
sion, which plays a key role for growth transformation
and immortalization of B lymphocytes. The efficiency of
three cationic carriers on the delivery of anti-LMP1-ON to
their site of action in Epstein Barr virus (EBV)-infected B
lymphocytes was investigated. Results showed that lipo-
somes, dendrimers or transferrin-PLL-conjugated ONwere
internalized by the cells at an extent several fold higher
than that of the naked oligomers. Using Superfect®, a den-
drimeric polycation with terminal amine groups, a higher
intracellular concentration of ONwas obtained as observed
by both cytofluorimetric and confocal microscopy analy-
ses. However, there was some evidence of toxicity induced
by the positively charged dendrimers on the lymphocytes’
membranes, and the lack of intracellularmRNA-ON duplex
formation and of LMP1mRNA degradation indicated a fail-
ure of this carrier.
Water-soluble phosphorus-containing dendrimers
[306,307], e.g., those possessing hydrophilic end groups
decorated with either positive or negative charges, also
show interesting biological properties. Loup et al. [308]
demonstrated that cationic phosphorus-containing den-
drimers may be used as in vitro DNA transfecting agents,
and that the generation has an important influence on
both efficiency of transfection and cytotoxic behavior.
Different strategies have been proposed to improve
transfection efficiency and biocompatibility. Arima et al.
[309] prepared a novel conjugate consisting of a dendrimer
(G3) with $-cyclodextrin bearing mannose (Man-$-CDE
conjugates) with various degrees of substitution of the
mannose moiety. The Man-$-CDE conjugate (G3, DSM10)
provided the highest gene transfer activity in different cell
types and provided new insights on the cellular associa-
tion of polyplex with Man-$-CDE conjugate (G3, DSM10).
Results also suggested that the conjugate has less cytotoxi-
city, able to escape from endosomes and to be translocated
into the nucleus. Similarly, Joester et al. [310] proposed
the use a series of amphiphilic dendrimers based on a
rigid tolane (diphenylethyne) core and possessing dif-
ferent numbers of C12 chains in the lipophilic dendron
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for efficient gene delivery. In their studies, it was evi-
dent the enhancement of the transfection efficiency by
amphiphilic dendrimers 2 (three C12 chains and nominal
charge 3+) and 3 (three C12 chains and nominal charge 9+)
as compared to reference compounds PEI, N-(1-(2,3-dio-
leoyloxy) propyl)-N,N,N-trimethyl ammoniummethylsul-
fate (DOTAP), and SuperFect®. The reason for this behavior
was consistent with the proton sponge endosomal escape
hypothesis.
Luo et al. [311] revealed the low cytotoxicity of
PEG-modified PAMAM and their efficiency on the DNA
delivery. These systems were obtained using low gen-
eration dendrimers with PEG chains, which mimics the
fractured high-generation dendrimers. In fact, the pro-
posedmolecules showed a 20-fold increase in transfection
efficiency as compared to that of partially degraded den-
drimer controls.
Zhang et al. [312] have investigated the effect of the core
structure and generation of PAMAM dendrimers on the
formation and transfection efficiency of the dendriplexes.
This work evaluated in vitro, the transfection efficiency of
a series of dendrimers with a trimesyl core (DT, three-arm)
usingCOS-7 cells,HeLa cells andprimaryhepatocytes.Den-
drimers derived from pentaerythritol (DP, four-arm) and
inositol (DI, six-arm) were used for comparison. Results
revealed that the minimal generation of 6 for DT for com-
plex with DNA, and 5 fpr DP and DI. Thus, the difference
in core structure resulted in different dendrimer flexibili-
ties, and consequently influenced the interaction between
the dendrimers and the DNA. As expected, the optimal
generation numbers at which dendrimers showed higher
transgene expression was 5 for DPs and DIs and 6 for
DTs. Importantly, DT dendriplexes show higher transfec-
tion efficiency, attributed to its buffer capacity inside the
endosome.
Boussif et al. work [313] uses PEI to test its potential
for gene delivery. PEI is a protonable amino nitrogen atom,
which makes the polymeric network an effective “proton
sponge” at virtually any pH, and can protect DNA from
nuclease activity. The PEI/luciferase reporter gene complex
was transferred into a variety of cell lines and primary cells
gave results comparable to that of lipopolyamines (the gold
standard).
Dung et al. [314] prepared dendriplexes of cholesteryl
dendrimers with antisense oligonucleotides (5:1). These
werebiologically active, andmediateddeliveryof antisense
oligonucleotide into HeLa cells in a moderate level. The
enhanced delivery of the antisense oligomer into nucleus
of the cells resulted in the expression of the reporter
gene product, a luciferase. Thus, that work demonstrated
that the increase of hydrophobicity by the conjugation of
cholesterol to dendrimer enhanced the delivery efficiency
of antisense oligonucleotide into cells.
Recently, Russ et al. [315] synthesized grafted-PPI
dendrimers of PPI dendrimers (G2 and G3) by surface
engineering with either oligoethylenimine (OEI) via ester-
degradable or PPI dendrimer (G2). They investigated their
potential as vectors for gene delivery both in vitro and
in vivo. In vitro transfection studies with the polyplexes
(surface-modifiedPPI dendrimers andplasmidDNApCMV-
Luc-firefly luciferase reporter gene) were carried out using
both Neuro2A neuroblastoma cells (ATCC®, CCl-131) and
B16F10 murine melanoma cells. Results showed that none
of the compounds was cytotoxic, and grafting of either
G2 or G3 core units with OEI led to enhanced transfec-
tion efficiency, irrespective of the core generation. Increase
of the generation of dendrimers did not enhance trans-
fection efficiency, in vitro. Prior in vivo studies, screened
possible haemolytic activity of the compounds. Contrarily
to previously reported PEI-induced erythrocyte aggrega-
tion, this work showed that none of the developed vectors
induced erythrocyte aggregation. In vivo, a clear influ-
ence of the dendrimers in the tumor gene expression
levels was observed, e.g., higher dendrimer core gen-
eration increased gene expression, demonstrating that
surface-modification and incorporation of ethyleneimine
core are key factors contributing to improve biocompati-
bility and transfection efficiency. Tziveleka et al. [316,317]
proposed different synthetic vectors for the prospective
application as gene transfection agents. Fourth-generation
PPI dendrimers partially or fully surface-modified with
guanidinium groups were able to complex with plasmid
DNA (pEGFP-C2 and pGL3 luciferase reporter vectors). In
vitro studies using human embryonic kidney (HEK 293)
and the monkey kidney fibroblast (COS-7) cells showed
that complete replacement of primary amino groups with
the hydroxylated moieties resulted in complete loss of
transfection efficiency. Contrarily, functionalization of the
dendrimers with guanidinium groups enhanced transfec-
tion efficiency. This enhancement was dependent on the
number of guanidinium groups at dendrimer periphery
and cell type. In fact, the fully guanidinylated-modified
dendrimer showed the best transfection efficiency. That is
attributed to an accumulation of the guanidinium group
at the dendrimeric surface, improving their penetrat-
ing ability. However, cytotoxicity studies demonstrated
that increase in the degree of guanidinylation increases
the dendrimers cytotoxicity. Thus, in light of these data,
functionalization strategies can be a valuable strategy
for superior transfection efficiency, but special attention
should be addressed to cytotoxicity, which can limit gene
transfer potency.
Choi et al. [318] adopted a different strategy to
improve transfection efficiency of PAMAM dendrimers,
demonstrating the positive effect of polyplexes on the
transfection efficiency by bonding Dex to PAMAM den-
drimers. In vitro studies using human embryonic kidney
(293) and mouse neuroblastoma (Neuro2A) cells, showed
that PAMAM-Dex/plasmid DNA (pCMV-Luc) complex had
a higher transfection efficiency as compared to PEI and
PAMAM, in the presence of serum proteins. Using 1,2-
bis-(o-aminophenoxy) ethane-N,N,N′,N′,-tetraacetic acid-
acetoxymethyl ester (BAPTA-AM), a glucocorticoid recep-
tor inhibitor, they proved that Dex-induced translocation
of the glucocorticoid receptor facilitate transport of com-
plexes into nucleus, thus enhancing transfection efficiency.
Great efforts have been made as an attempt to clar-
ify the mechanism(s) of transfection. Manunta et al. [319]
reported on the route by which dendriplexes are internal-
ized and mediate gene transfer. This work demonstrated
that internalization is dependent on the cell type, and is a
successful example of dendrimer application as a non-viral
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vector for gene delivery. The report showed that transfec-
tion of the dendriplexes may occur via different pathways,
but in cells expressing caveolae, results suggest that gene
deliverymight be occurring by a caveolin-dependent path-
way. Ruponen et al. [320] carried out a comparative study
to investigate the performance of both cationic lipids
(e.g., DOTAP and 1,2-dioleyl-3-phosphatidylethanolamine
(DOPE)) and polymers (e.g., PEI, PAMAM dendrimers and
PLL) for gene delivery. The study investigated the effect
of interactions of extracellular polyanionic glycosamino-
glycans (GAGs), such as hyaluronic acid (HA), chondroitin
sulfate, and heparan sulfate with positively charged plas-
mid DNA complexes on the transfection efficiency. The
results showed that polycations condensed DNA more
effectively than monovalent lipids. Furthermore, poly-
plexes (PEI, PLL) were internalized by the cells more
efficiently than lipoplexes. It was also found that sul-
fated GAGs (heparan sulfate, chondroitin sulfates B and
C) completely blocked transfection, except in the case of
liposomeswith DOPE.Moreover, it was found that sulfated
GAGs induced DNA release from PEI complexes, but that
DNA release from the complexes was not required for the
inhibitionof transfection. TransfectionbyPEI, PAMAMden-
drimers was inhibited by HA. This comprehensive study
suggested that cell-surface GAGs, namely heparan sulfate
can inhibit transfection mediated by both cationic lipids
and polymers indicating that mechanistic information can
help to develop more efficient vectors for gene delivery.
The protection of DNA from in vivo degradation by the
vectors is another key feature for success in gene delivery.
Diaz-Mochonet al. [321] showed that ahybrid combination
of PAMAM and peptide dendrimers, the so-called pep-
toid dendrimers, were able to transfect cells with higher
efficiency than the PAMAM counterpart, and were non-
toxic. In part, this work supported previous findings which
demonstrated that combination of primary and secondary
aminesgenerates a “proton sponge”effect,whichcan facili-
tate theDNA transfectionprocess, bypromoting the release
of the plasmid from the cytoplasmic lysosome. Thus, effi-
ciency of dendrimer/DNA complexes may be favored by
prolonging the release of plasmid.
An early stage work reported by Herrmann et al. [322]
described the synthesis ofpolyphenylenedendrimers func-
tionalized with lysine residues or substituted with short
peptide sequences composed of five lysine or glutamic acid
repeats and a C- or N-terminal cysteine residue. This group
postulated that these amino acid and peptide functional-
ized dendrimers may be of interest as model compounds
to study DNA complexation.
There are few papers which employ dendritic PLL as
a gene delivery carrier, either alone or in combination
with linear polymers or PEG. However, Männistö et al.
[323] showed that the shape and charge of these non-
viral vectors greatly influence their complexation with
DNA and ultimately their transfection efficiency. Their
study showed the ability of PLL dendrimers for com-
plexing with DNA. Linear polymers were more efficient
than dendritic ones. At low Mw of PLL, DNA-binding and
condensation were less efficient, particularly with den-
drimers. PEGylation did not decrease DNA condensation of
PLLs at less than 60% (fraction of Mw) of PEG. Moreover,
introduction of PEG stabilized the complexes sterically.
Internalization of PLL/DNA complexes was high and PEGy-
lation increased the transfection efficacy. However, the
overall transfection level of PLL was low, possibly due to
inadequate escape of the complexes from endosomes or
poor releaseofDNA fromthecomplexes.Higashi et al. [324]
studied the interaction of water-soluble PLL-shelled den-
drimers possessing various PLL segment (n=5–40) with
DNA by circular dichroism spectroscopy, dynamic light
scattering, and melting behavior of double-stranded DNA.
Double helical DNAswere found to complexwith dendritic
PLLs (G3) [5,10,20] primarily via electrostatic interactions.
Moreover, a longer PLL-containing (G3) was found to
interact with DNA more effectively than a shorter one.
Okuda et al. [325] have also investigated the effect of
substituting terminal cationic groups in PLL on the gene
delivery into cells, in particular, the effect of guanidinium
groups on the transfection. Monodispersed PLL (G6) den-
drimers in which external amino acids were replaced by
arginines and histidines were synthesized. A particular
attention was given to clarify whether histidine shows the
activity as an endosomal disruption agent. DNA-binding
and transfection studies revealed that arginine-terminated
PLL dendrimers could bind to the DNA more efficiently,
and presented higher transfection efficiency as compared
to those for histidine-terminated PLL. In fact, histidine-
terminated PLL did not mediate transfection. Despite,
the terminal histidines of PLL dendrimers, especially the
imidazole groups, had a key role in the pH-dependent com-
plex formation and transfection (neutral and acidic pHs).
The unique character of histidine-PLL dendrimers is most
promising.
As aforementioned, cationic PAMAM dendrimers have
proved to efficiently mediate transfection of DNA into a
variety of mammalian cells, in vitro. However, as high-
lighted, the major drawback of high-generation cationic
dendrimers is their associated cytotoxicity. Anionic den-
drimers, on the other hand, have shown no cytotoxic effect
on cells over a broad range of concentrations. Hussain et
al. [326] have reported the successful use of ONs conju-
gated with pentaerythritol-based anionic dendrimers in
inhibiting cancer-cell growth. In vitro studies using cancer
cells showed that ONs-dendrimer conjugates enhance the
cellular uptake, up to four times as compared to that for
naked ONs. These data clearly demonstrated that anionic
ONs-dendrimer conjugates may represent attractive alter-
natives to cationic non-viral vectors for the delivery of gene
silencing ONs. However, it is not known whether the sys-
tem may facilitate the delivery of duplex siRNA for gene
silencing by RNA interference. Therefore, further studies
are necessary to evaluate the full potential of the deliv-
ery system. Similarly, Vincent et al. [327] investigated the
efficacy in cancer therapy of non-viral gene transfer using
the anti-angiogenic angiostatin (Kringle 1–3) and tissue
inhibitors of metalloproteinases (TIMP) genes. This study
revealed that it was possible to inhibit tumor growth and
angiogenesis by using PAMAM dendrimers-like superfec-
tant associated with 36-mer anionic oligomers (ON36) for
delivering angiostatin and (TIMP)-2 genes. This strategy
was validated in vivo, since i.t. angiostatin or TIMP-2 gene
deliveryusing thesedendrimers inhibited tumorgrowthby
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71% and 84%, respectively, while combined gene transfer
resulted in 96% inhibition of tumor growth.
Electrophoretic studies carried out by Kuo and Lin [328]
have demonstrated that fifth-generation PAMAM and PPI
dendrimers altered or blocked the mobility of RNA iso-
lated from human macrophage-like cells (U937 cell line)
and mouse fibroblast NIH/3T3cells previously exposed
to DNA/dendrimer complexes. At higher dendrimer:DNA
ratio, dendrimers interacted with RNA after isolation, but
gene expression of these complexes was not affected.
Electrostatic forces were found to be responsible for the
dendrimer-induced alteration in RNA mobility. Because
RNA isolation is routinely used for biological applications,
such dendrimer-induced alteration in RNAmobility should
be accounted for when further processing RNA for related
applications, and the use of high ionic strength solvents
(2MNaCl solution) to disrupt the electrostatic forces bind-
ing dendrimers to RNA is advised.
A final key aspect in the gene delivery is related to
the need to control gene transfection. This can be accom-
plished by developing controllable and non-toxic gene
delivery systems that are stimuli-responsive. For exam-
ple, Nishiyama et al. [329] proposed an innovative strategy
based on PCI gene delivery. In their work, they have devel-
opeda ternary complexes (size between100andcomposed
of a core of and cationic peptides (C(YGRKKRRQRRRG)2)
that were enveloped in the second generation aryl ether
dendrimers (32 carboxyl groups at the periphery) with a
phtalocyanine core (photosensitizer). In vitro transfection
studies using human cervical epithelioid carcinoma (HeLa)
cells demonstrated that this ternary system enhanced
(>100-fold) transgene expression as compared to con-
ventional reagents, such as PEI and Lipofectamine, in
vitro. Moreover, it was shown that PCI-mediated gene
delivery reduced phototoxicity of the ternary complexes.
For the in vivo studies a reported gene was used. Flu-
orescence microscopy studies of rat conjunctival tissue
revealed that the ternary complex positively induced gene
delivery by PCI. That work demonstrated that polyplex-
polycations significantly affect both transfection efficiency
and toxicity. Therefore further optimization of this type
of systems should involve research on the use of other
polycations. Thus, PCI provides us with an opportunity
to develop efficient light-inducible gene delivery sys-
tems. Shieh et al. [330] also investigated photo-triggered
gene transfection by core-modified PAMAM dendrimers
(G4). In their work, a 5,10,15-tri(4-acetamidophenyl)-20-
mono(4-carboxylphenyl) porphyrin (hydrophobic core)
was introduced into the PAMAM dendrimers by activation
with DCC and N-hydroxysuccinimide. In vitro charac-
terization studies revealed that porphyrin core-PAMAM
dendrimer conjugates were able to complex with green
fluorescent protein (EGFP) plasmidDNA, and that the inter-
nalization by HeLa cells was concentration-dependent.
Moreover, results from phototoxicity showed that with-
out irradiation more than 94% of the cells survived when
incubated with conjugates at a concentration of 20!M.
However, the complexes induced toxicity at 50!M. For
photodynamic therapy, results show that conjugation of
porphyrin core to dendrimers did not increase the cyto-
toxicity of the PAMAM dendrimer below 20!M, but
significantly induced cell death after suitable irradia-
tion. Nevertheless, the expression of EGFP was enhanced
in HeLa cells using the PCI treatment. Thus, that study
demonstrated that PAMAM dendrimers conjugated with
porphyrin core can be an efficient and safe vector for PCI-
mediated gene delivery.
Dendrimers are one of the most useful non-viral gene
delivery systems. Their ability to transfect cells without
inducing toxicity and be tuned for stimuli-induced gene
delivery confers a great advantage over other gene delivery
vectors for use in vivo.
3.5. Theranostics applications of dendrimers and
dendronized polymers
Although opportunities to develop nanotechnology-
based drug delivery systems extend into all therapeutic
classes of pharmaceuticals, the development of effective
diagnostic and therapeutic, e.g., one-package systems that
can target different tissues, while releasing one or mul-
tiple therapeutic agents under an external stimuli have
attracted a great deal of attention. For example, in can-
cer therapy, anti-cancer agents candamagebothmalignant
and normal cells. Additional problems include instability
of the drugs/growth factors in the biological milieu and
short half-time, systemic migration, and premature drug
loss through either rapid clearance by Mo/Mac, and/or
metabolism. The design of most sophisticated systems
should also consider the need for temporal release of
the drug(s). Thus, dendrimers can be tuned for: (i) be
stimuli-responsive nanocarriers, (ii) include molecular-
tags, (iii) possess high payload efficiency, (iv) decrease
dosage requirements as well as re-dosage frequency and
(v) target delivery and minimize drug migration, thus
suppressing secondary effects during drug treatment. For
example, Kuo et al. [331] investigated in vivo, the inter-
actions of second and third generation PPI dendrimers
withhumanmacrophagesU-937, since thesemolecules are
primarily removed from circulation by the mononuclear
phagocyte system. The effect of the type of dendrimer and
concentration on the content of intracellular responses-
reactive oxygen species (ROS), mitochondria membrane
potential, cell size and complexity, and cell cycle pro-
files were investigated. Although the concentrations of
PPI dendrimers used (40–300!gmL−1) were not cyto-
toxic, various intracellular responses in dendrimer-treated
macrophages occurred in a time-dependent manner.
Moreover, the intracellular responses were found to be
dependent on the dendrimer generation. This work nicely
illustrates that a better understanding of the molecular
action of these nanosystems in the cellular system may be
an advantage for best design of safer and more effective
delivery systems.
As previously stated herein, dendrimers fulfill these
requirements as they can be stimuli-responsive and
controlled-release systems for nucleic acids, bioactive
molecules and peptide/protein delivery. Due to the pos-
sibility of tailoring the end groups, dendrimers are able to
interact with the target, such as cell walls and/or proteins
[156]. The external functional groupsmay allow the simul-
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Fig. 9. Schematic representation of dendrimers with external bind-
ing to the drug and fluorescent-probes for application in theranostics
(one-package system). It is possible to follow the biodistribution, inter-
nalization and intracellular trafficking within cells. The use of targeting
devices such as antibodies to augment specificity is also possible. The
drug can be linked to dendrimers using different spacers or bonds (X),
which can be cleaved under a certain external stimuli, thus stimuli- or
bio-responsive release is an additional possibility.
taneous, covalent bonding to therapeutic drugs, targeting
devices and fluorescent-probes (Fig. 9).
Recently, a combination of polymer chemistry and
imaging science approaches has led to the generation of
polymer-based bioimaging probes for the diagnosis and
treatment of different diseases. The ultimate goal of in vivo
imaging is to achieve highly sensitive and reliable imaging
techniques viable for diagnosis in personalized medicine
for delivering drugs, following their distribution, andmon-
itoring therapy. This concept (theranostics) is based on
the “find, fight and follow” approach. New probes with
enhanced capabilities and performance should be devel-
oped specific to nano-imaging techniques. Key research
priorities for targeted delivery and in vivo imaging should
address: (i) design of nanostructures with stealth proper-
ties that prevent them from being opsonised or cleared
before reaching the target cells, (ii) ability to penetrate
into cells and crossover biological barriers like the BBB,
uptake and recyclingof nanostructures, (iii) nanocarriers or
strategies that selectively targets diseased cells, tissues and
organs, (iv) trans-endocytosis of nanostructures, (v) safety
evaluation (in vitro/in vivo cytotoxicity, haemocompatibil-
ity and immunogenicity), in vivo carrier biodistribution,
and (vi) compatibilitywith external activation bymagnetic
field, ultrasound, X-ray, or optics to trigger the therapeutic
activity. For example, theKobayashi et al. [332]have shown
that a dendrimer-basedmagnetic resonance contrast agent
may be useful for in vivo detection of renal tubular damage.
By its turn, Rietveld et al. [333] developed dendrimerswith
tetrabenzoporphyrin cores for in vivo oxygen imaging.
While it is promising to incorporate both therapeutic
agents andmolecular-tags on the dendrimers, and improve
their potency [74], the possibility of combining diagnosis
and therapy inmulti-functional dendrimer-basednanosys-
tems can allow the early detection, targeting and treatment
of several diseases.
Thomas et al. [334] have linked PAMAM dendrimers
(G5) with FITC for tracking, and two different antibodies,
60bca and J591, that bind to CD14 and prostrate spe-
cific membrane antigen (PSMA), respectively. This work
showed the receptor specificity as the conjugates bound
to specific antigen expressing cells. Shukla et al. [335] syn-
thesizedPAMAMdendrimers (G5) conjugated to anti-HER2
monoclonal antibodyby tagging the formulationwith alex-
aFluor (AF). Flow cytometry studies revealed the uptake of
conjugate by HER2 expressing cells, while no such affinity
was found for MCA-207 control cells that did not express
HER2, in vitro. Another good example of such versatile den-
drimeric systemswas put forward by Baek and Roy [336]. A
well-defined multivalent T-antigen (Thomsen-Friedenrich
antigen)-glycoPAMAM dendrimer was synthesized, aimed
at applications in the detection and immunotherapy of car-
cinomas such as breast cancer. In another study [337], they
synthesized a heterobifunctionalized dendritic l-lysine
core bearing biotin and T-antigen by coupling the thiolated
T-antigen derivative to N-chloroacetylated glycylglycyl l-
lysine dendritic cores.
According to the literature, the success of entrap-
ping small molecules inside the dendrimer depends on
the mutual properties between the host and the guest
molecules. For example, Domanski et al. [84] reported
attempts to entrap small fluorescent-probes commonly
used to evaluate membrane fluidity inside the dendrimer.
This work showed that 12-(9-anthroyloxy) stearic acid
(12-AS), a non-polar fatty acid derivative, was success-
fully incorporated into the PAMAM dendrimers cavities,
while on the contrary, 1-(trimethylammoniumphenyl)-6-
phenyl-1,3,5 hexatriene p-toluenesulfonate (TMA-DPH), a
amphiphilic salt possessing a positive charge, was not.
Kolhe et al. [338] demonstrated that ibuprofen pre-
dominantly forms a complex with PAMAM (G3 and G4)
dendrimers because of the ionic interaction between the
–NH2 end groups and the carboxyl group of ibupro-
fen. In this work, they demonstrated that the in vitro
release of ibuprofen from drug–dendrimer complex is
appreciably slower compared to pure ibuprofen. More-
over, the FITC-labeled dendrimer-complexed drug enters
human lung epithelial carcinoma A549 cells much faster
than pure drug, suggesting that dendrimers may be
able to carry the complexed drug inside cells efficiently.
That group [57] synthesized a fourth-generation PAMAM
(PAMAM-OH) dendrimer covalently linked to ibupro-
fen using dicyclohexylcarbodiimide (DCC) as a coupling
agent. A high payload nanocarrier was obtained; 58
molecules of ibuprofen were covalently conjugated to
one molecule of PAMAM-OH (G4) dendrimer. FITC-labeled
dendrimer–drug conjugate nanoparticles internalization
was evaluated in vitro once using A549 cells. The phar-
macological activity of the dendrimer–ibuprofen conjugate
was compared to pure ibuprofen at various time points
by measuring the suppression of prostaglandin E2. Results
demonstrated the high internalization efficiency of the
FITC-labeled dendrimer–drug conjugate and superior ther-
apeutic activity due to faster prostaglandin E2 suppression.
Thus, the results suggest that the dendrimer–ibuprofen
conjugate improve the drug efficacy by enhanced cellu-
lar delivery, and may produce a rapid pharmacological
response. For example, several ligands are known to be
associated with tumor. Ligand based dendritic polymers
have been attracting great deal of attention for find appli-
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cations in cancer-cell-specific targeting [108] and tumor
therapy [339].
Transferrin is a #-globulin (#1-glycoprotein) and facil-
itates the transport of ferric ion (Fe3+) through transferrin
receptors on the plasma membrane. In fact, the use of
transferrin as a ligand has been explored as a suitable
delivery system for site-specific delivery to tumors [340].
PLL covalently linked with transferrin for delivery of ONs
when exposed to human leukemic (HL-60) cells have been
stated to promote apoptosis to a greater extent as com-
pared to free ONs. Another paper [341] demonstrated
that PEGylated poly(cyanoacrylate) nanoparticles conju-
gated to transferrin were effective on the delivery of
paclitaxel (PTX), an anti-tumor drug. PEGylation prevented
aggregation of nanoparticles and transferrin effectively
determined tumor site. An innovative study by Choi et al.
[108] consisted of the development of dendrimers conju-
gated to different biofunctional moieties [FITC for imaging,
and folic acid (FA) for targeting], linked together using
complementary DNA oligonucleotides to produce clus-
tered molecules for targeting tumor cells through folate
receptors. This step forward allowed obtain both efficient
DNA-linked dendrimer clusters for intracellular imaging
and therapeutics, and circumvent the tedious synthesis of
multiply-functionalized dendrimers.
Instead of linking oligonucleotides to the dendrimers,
Majoros et al. [342] synthesized amulti-functional PAMAM
dendrimer (G5) conjugated with FITC, FA, and PTX. In vitro
studies have shown that drug-free dendrimer conjugates
were not cytotoxic even at high concentrations. On con-
trary, drug-loadeddendrimerconjugateswere toxic toboth
folate receptor-positive and folate receptor-negative cells
as a result of non-specific binding at concentrations around
200nM.
Another good example of PAMAM dendrimer-based
multi-functional devices (target the desire cells, releasing
the desired drug and monitoring their internalization-
fluorescent probe) has been reported by Islam et al. [343].
This group partially acetylated PAMAM dendrimers (G5)
that were then conjugated with FITC, FA and MTX. These
weredevised to target tumor cells through the folate recep-
tor, while releasing an anti-tumor drug intracellularly.
They showed that HPLC analysis is a valuable technique
to determine the purity and stability of dendrimer-based
complexes.
Yang et al. [344] synthesized FITC- and biotin-linked
PAMAM dendrimer (G5) conjugates and investigated their
ability for targeting cancer cells. The bifunctional conjugate
(FITC–biotin–dendrimer) exhibited much higher internal-
ization by HeLa cells than the conjugate without biotin.
The uptake was found to be energy- and dose-dependent,
and could be effectively blocked by dendrimer-conjugated
biotin. The results indicate that the biocompatible biotin-
dendrimer conjugate can be a promising nano-platform for
therapy and diagnosis of tumors.
Epidermal growth factor (EGF) is an important factor
that controls thedisposition of neoplastic cells andpotenti-
ates transcription and proliferation of cells. Human growth
receptor (HER-2) is amember of EGF family and their num-
ber is augmented in several tumors [345], and hence, it
provides a potential target for immunotherapeutic agent.
Nanoparticles having a size in the range 1–10nm have
the capacity to diffuse into tumor cells. This helps to
overcome limitations relating to chemotherapy using free
drug such as poor in vivo/in vitro correlation and over-
come other possible resistances offered by tumors. In fact,
Tomalia [346] has also proposed the use of ∼5nm sodium
salt-PAMAM dendrimers (G4.5) nanoparticles possessing
a 1,4-diaminobutanecore, as multi-purpose nanodevices
for oncology drug delivery and diagnostic MRI contrast
agents.
Relevant scientific data were recently reported by Saad
et al. [347]. In this interesting work they investigated
the role of different nanocarriers (linear polymer, PAMAM
dendrimer and liposomes) containing the same bioactive
agents, in tumor-specific treatment and imaging. In their
comprehensive work it was demonstrated for the first
time, that the targeting of nanocarriers to tumor-specific
receptorsminimizes the influenceof the architecture, com-
position, size and Mw of the nanocarriers on the efficacy
of imaging and cancer treatment. This step forward, illus-
trates that potential of the nanocarriers can only be fully
exploited with a much better understanding of how such
structures interact with the body and its components, in
vitro and in vivo.
4. Concluding remarks and future outlook
Nanotechnology and medicine research are merging
with other fields, leading to completely new science and
superior technological platforms, such as those recently
reported for regenerative medicine and neurosciences.
The main aim of this review article was to summarize
the unique properties, ability to design and improve the
biological performance of dendrimers. This novel class
of polymers and their derivatives exhibit unique physic-
ochemical and biological properties, which have great
potential for use in a variety of applications, including tis-
sue engineering and regenerative medicine, as discussed
herein.
Their compatibilitywith nanoscale building blocks such
as genetic material, bioactive molecules and fluorescent-
probes, which make them even more versatile than other
nanomaterials, indeedprobablywithunique feature foruse
in theranostics was also emphasized. The development of
dendrimers occurs at a time when common medical prac-
tice is based on symptom control, and research is focused
on the best drugs to relieve the impact and progression of a
given disease. Dendrimersmay be used as tools to diagnose
pathologies in an early stage thus helping manage disease
in a sustainablemanner. There is however, the need to con-
duct comprehensive research in vivo, to better understand
and assess their true value as multi-functional packages.
In particular, we still do not knowwhether these synthetic
polymers, once they entered the body can cause damage
to other tissues. Thus, much effort is required to evaluate
the risk of bioaccumulation and redistribution. Research on
their adsorption and interaction with biological surfaces,
the associated uptake mechanisms, long-term effects, and
bio-elimination needs also to be determined. Hence, new
and unexplored characteristics of nanoscale are opened,
andunsettled issues of biocompatibility,whichwill remain
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a key challenge without a definitive near term answer.
Progress in the field of dendrimers and derivativeswill cer-
tainly depend on other not less important aspects. In order
to be effective, dendrimer-based products should be based
on scientific evidence for their usefulness andmust be eas-
ier to translate from laboratory to the clinic, in other words
be quality-controlable, cost-effective and sustainable. Last,
but not the least, their application should be validated from
the regulator’s viewpoint, worldwide.
As afinal remark, the process of converting basic discov-
eries into marketable products can be long and hard, but
since the discovery of dendrimers we can envision things
never possible before and expect many innovations in the
puzzling field of regenerative medicine.
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